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ABSTRACT

Several lines of evidence strongly link prostaglandins (PGs) and leukotrienes (L Ts)
to cancers of the intestine. Epidemiological studies showed aspirin and aspirin-like
compounds reduced the relative risk of intestinal cancer in humans by 40-50%.
Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause regression of intestinal tumors
in humans and laboratory animals as well. The precise mechanism of antitumor effect of
these NSAIDs is uncertain, but it has been presumed the effect is due to their ability to
inhibit prostaglandin biosynthesis. This dissertation is designed to investigate the effect of
modifying eicosanoid biosynthesis by NSAIDs and dietary manipulation on tumor load in a
mouse model (Mini+) containing a germline defect of the APC gene. Mini+ mice were
treated with sulindac ( 320 ppm), aspirin (400 ppm) and indomethacin (9 ppm) to inhibit
and dietary arachidonic acid (I. 5 wt %) to augment eicosanoid biosynthesis. Sulindac
treatment reduced tumor number by > 90%, with the recurrence of tumor load following
removal of treatment. In mice with established tumors, sulindac reduced tumor number by
28% and 75% after 2 and 4 days treatment, respectively. Surprisingly, sulindac treatment
did not alter the levels of eicosanoids. Both indomethacin and aspirin are potent inhibitors
of prostaglandins; however, only indomethacin significantly reduced the tumor number.
Elevating prostaglandin E2 by 44% following dietary arachidonic acid supplementation had
no effect on tumor load. In summary, the data indicate a discordance between the impact
of different NSAIDs on eicosanoid biosynthesis and their antitumor activity.
V
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PART I

INTRODUCTION

I

Cancer is the second leading cause of death in the United States. Colorectal
cancer represents the second leading cause of death from all cancers and accounts for a
third of the estimated new cancer cases ( 1). The formation of eicosanoids (prostaglandins
and leukotrienes) derived from arachidonic acid (� 20: 4n-6) have been strongly linked
to cancer of the intestines. It is hypothesized that prostaglandins and leukotrienes may
participate in colon carcinogenesis and in tumor development (2-5).
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as sulindac and aspirin, are
effective inhibitors of prostaglandin H synthase (PGH synthase) ( 6-8) and an inverse
relationship between NS AID use and the relative risk of mortality due to colorectal cancer
has been demonstrated (9-11), as well as reduction in tumor load in human familial
adenomatous polyposis (FAP) patients ( 12-14) and in animal models with chemically
induced intestinal cancers ( 15, 16).
The C57BL/6J-Min (Mini+) mouse strain carries a dominant germline mutation in
one allele of the tumor suppressor gene adenomatous polyposis coli (Ape) at nucleotide
2549 ( 17). This model is highly susceptible to spontaneous intestinal adenoma formation.
The homozygous (Min/Min) mice are not viable, whereas the heterozygous (Mini+) mice
develop over 30 adenomas throughout the entire intestinal tract ( 18). The Mini+ mouse
model is currently being used to study human intestinal tumorigenesis because it is
genotypically and phenotypically analogous to the inherited human disease FAP ( 17, 19).

2

PART II

REVIEW OF THE LITERATURE

3

INTESTINAL CANCER
Cancer is the second leading cause of death in the United States. About 25% of all
deaths are due to cancer and is surpassed only by deaths due to heart disease which
accounts for approximately 1/3 of the mortality. Colorectal cancer, next to lung cancer,
represents the second leading cause of deaths from cancers in the Unites States. The
colon is among the most common site for new cancer cases for both genders in the U.S.
Colon cancer is only behind prostate and lung cancers in males and breast and lung
cancers in females (I).
Colorectal cancer is common in Western societies, but rare in developing
countries; however, a sharp increase in the incidence of colorectal cancer has been
observed in Eastern Europe and Japan in the last decade. Comparative studies of the
international incidence of colon cancer indicate that there is a more than I 0-fold difference
in incidence between the countries with the highest ( the Japanese population in Hawaii for
male and in New Zealand for female) and the countries with the lowest rate (in Africa and
India for both genders) (20, 2 1), suggesting environmental factors may play an important
role in incidence.
The origin of cancer development has been extensively studied during the past
twenty years. Both genetic and environmental factors are considered as the responsible
risk factors for human colon cancer (22). Most cancers of the colon occur as a result of a
somatic mutation, and as such, sporadic colorectal cancer accounts for approximately 76%
of colorectal cancer cases (23, 24). Some forms, however, are highly prevalent in families,
where there appears to be a predisposition to the cancer as a result of a germline mutation.
4

In familial adenomatous polyposis (FAP), individuals develop large numbers of polyps in
the colon . This form of hereditary colon cancer represents approximately 1% of
colorectal cancer cases and is characterized by I 00-1OOOs of intestinal adenomas,
concentrated primarily in the colon . FAP patients develop colonic adenomas over a
duration of 20-30 years. The polyps (adenomas) are not initially malignant; however, if
left in place, they can eventually evolve into invasive carcinomas. A second form of
hereditary colon cancer is known as hereditary nonpolyposis colon cancer (HNPCC)
(accounts for about 5% of colorectal cancer cases). In contrast to FAP, there is no early
polyp phase; however, once polyps form, they rapidly progress into carcinomas. Of all the
risk factors associated with colorectal cancer, diet is among the most important
environmental determinants in the etiology of this disease (25). High intakes of fat,
saturated and polyunsaturated, are characteristic of the typical Westem industrialized diet,
and these fats are believed to exert a strong effect on the promotion and progression of
colorectal tumors (25, 26).

MOLECULAR GENETICS OF COLON CANCER
The development of human intestinal cancer involves progression through a series
of distinct morphological stages and has long been thought to be a complex and multistep
process (27-31). The progressive evolution of colon cancer develops slowly over years or
even decades . With regard to genetic risk factors, several studies have revealed numbers
of activated oncogenes, inactivated tumor suppressor genes and mismatch repair genes
that appear to be involved in initiation, promotion, proliferation, and transformation (Table
5

2. 1) ( 32). Recently, it has become possible to identify the molecular events that underlie
the aberrant cell growth leading to colorectal cancer ( 3 3, 34). Analysis of specific genetic
alterations at each of these morphological stages in humans has lead to the development of
a model implicating an interplay of the accumulated mutations in several tumor suppressor
genes and oncogenes in tumor formation and progression (Figure 2.1) (27, 29).
Tumor suppressor genes and colon cancer

Tumor suppressor genes, which generally have inhibitory functions to restrain cell
growth, proliferation and malignant transformation, were first found in the mid 1980s and
had drawn the attention of cancer research because they are commonly mutated in human
cancer and the spectrum of mutations in these cancers provides clues to the etiology and
molecular pathogenesis of neoplasia (28-29, 3 3). The accumulation of these genetic
changes in tumor suppressor genes plays a key role in the transition from a benign
adenoma into an invasive growing carcinoma (27, 29, 35). A mutatedp53 gene (named
for its 53-kDa molecular weight gene product) has been found in DNA samples prepared
from more than half of human tumors examined to date, making it the most common gene
mutation associated with human cancer causation ( 36).
A loss of specific chromosomal regions occurs frequently in colorectal neoplasia.
Usually the losses involve only one of the two parental chromosomes present in normal
cells. These allelic losses have been interpreted as evidence that the regions affected
contain tumor suppressor genes, whose products normally regulate growth and
differentiation in a negative fashion and thus indirectly suppress neoplastic development
( 37). Loss of heterozygosity was most frequently observed in chromosomes Sq, l 7p and
6

Table 2. 1. Genetic risk factors related to colorectal tumorigenesis §

Gene

Locus

Oncogene
K-ras (Kirsten rat sarcoma)

12pl 2. l

Suppressor genes
APC ( adenomatous polyposis
coli - responsible gene)

Length
(aa)

189

5q2 1

2843

p53 (protein 53 kDa

17p l 2

393

DCC ( deleted in colorectal carcinoma)

18q2 1. 3

1447

5q2 1

829

Li-Fraumeni - responsible gene)

MCC ( mutated in colorectal cancer)
DNA mismatch repairing genes
hMSH-2
hMLH-2
(All involved in HNPCC
hPMS- I
- responsible genes)
hPMS-2
§

2p16
3p21
2q31-33
7q22

1037
756
932
862

Modified from Ref 3 2
aa: amino acid; p: short arm of chromosome; q: long arm of chromosome
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A genetic model of colorectal tumorigenesis. Colorectal tumorigenesis proceeds through a series of
genetic alterations involving oncogenes and tumor suppressor genes. Mutation of the APC gene leads to
abnormal epithelial proliferation and differentiation. An increase in the prevalence of K-ras mutation is
evident in intermediate adenomas. Deletion of the DCC gene occurs more frequently in late adenomas.
Deletion and mutation of the p53 gene is associated with the development of carcinomas ( Modified from
Ref. 27, 28).

18q, suggesting the presence of candidate suppressor genes in particular regions of these
chromosomes. Studies directed at the identification of these genes led to the finding of the
p53 gene on chromosome 17p (38, 39), the DCC gene (deleted in colorectal cancer) on
chromosome 18q (40-42), and the MCC gene (mutated in colorectal cancer) and APC
gene (involved in adenomatous polyposis coli), both on chromosome 5q (43-46).
The current concept is that the APC gene has a gatekeeper function in the
colorectum, i.e., this gene can be considered rate limiting for neoplastic growth and the
dysplastic phenotype ( 47). The mutated APC gene appears to permit the outgrowth of
early colonic polyps and therefore is thought to play a crucial role in tumor formation and
progression. Recent advances in molecular genetics revealed that a germline mutation of
APC gene is responsible for the inherited colon cancer associated with F AP. In addition,
most sporadic cancers have a corresponding APC mutation and thus can occur randomly
in colonic epithelial cells in most human colonic tumors. Later, a somatic mutation may
activate a ras oncogene, creating a more advanced polyp that is, however, still benign.
Over a period of years, this polyp may sustain mutations in its DCC and p53 suppressor
genes, and these mutations in turn appear to lead to the more autonomous, uncontrolled
growth of the colon carcinoma cell (27).
Tumor suppressor gene--adenomatous polyposis coli (APC)

It is generally thought that genetic predisposition plays an important role in the
induction of colon cancer in certain individuals. Current evidence suggests mutation of a
gene on chromosome Sq is involved in the early stages of development of colorectal
tumors. For example, allelic loss of a gene on Sq is noted in the smallest adenomas
9

examined, suggesting this is an early event, if not the initiating event, in colorectal
tumorigenesis ( 47, 48). One particular type of genetic change that predisposes individuals
to colon cancer is a mutation on the APC gene (43, 45, 46, 49). On the basis of genetic
linkage analysis and subsequent chromosomal position cloning, the APC gene was mapped
to human chromosome 5q2 1 (43, 45, 46, 49-52).
Alterations in the human APC gene have been demonstrated to play a role in
familial adenomatous polyposis (FAP) as well as sporadic cancers (24). Germline
mutations in the APC gene are known to be present in individuals with FAP, an autosomal
dominant inherited predisposition to colorectal cancer (53). Somatic APC mutations can
be found in over 70% of human sporadic colorectal tumors and this mutation occurs as an
early event during the colorectal tumorigenesis as frequency of this mutation remains
constant as tumors progress from benign to malignant stages (24). Recently, a mouse
model system has been developed in which mice have a mutation mapped to chromosome
18 and is tightly linked to Ape, the mouse homolog of the human APC gene (54).
APC is a large gene consisting of 15 exons encoding a protein containing 2843amino acid residues (Figure 2. 2). Exons 1-14 are small, while exon 15 is large and two
thirds of disease-causing mutations are found in the 5' (proximal) segment of this exon
(55, 56). Antibodies to the APC protein have identified a 300 kDa cytoplasmic protein
expressed in epithelial cells (57). This APC gene product contains an NH2-terminal
domain with potential to form a coiled-coil structure, a central region characterized by a
repeated 15- to 20- amino acid sequence, and a cluster of basic amino acids in the COOH
terminal region (44, 45). The features of the APC protein have been well elucidated. The
10
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extreme NH2-terminal region is responsible for APC homodimerization. The first 45
amino acids of APC are necessary and the first 171 amino acids are sufficient for this
interaction. Most mutant APC proteins still retain the capacity to associate with wild-type
APC both in vivo and in vitro (58, 59). Recent studies strongly suggest that APC
associates with alpha- and beta-catenins which are known to bind to the cell surface
molecule E-cadherin. Some of the repeats in the central region of the protein appear to be
responsible for this interaction (60, 61). Catenins are considered to be involved in the
transmission of adhesion signals ( 62) and it is proposed that APC protein may affect the
interaction between catenins and E-cadherin, thus influencing cellular adhesion and
possibly intercellular communication (60, 6 1). Three distinct interactions have been
described for the carboxyl terminus of APC. When overexpressed in colon cancer cell
lines, the final 700 amino acids of APC can interact with microtubules (63, 64). Yeast
two-hybrid analysis indicated that amino acids 2560-2843 of APC can bind a protein of
unknown function called EBI (65). Recently, two-hybrid studies have also shown that the
final 72 amino acids of APC are sufficient for binding to the human homolog of
Drosophila discs large tumor suppressor protein (DLG) (66). While the functional
significance of these three carboxyl domains is unclear, binding of APC to microtubules
and DLG may also regulate cell adhesion. It has been reported that a trimeric complex of
DLG, APC, and P-catenin can be immunoprecipitated from mouse brain cells (66). The
interaction of APC with microtubules has been hypothesized to mediate signals from P
catenin/cadherin to the cytoskeleton (6 3, 64).
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While it remains unclear precisely how disruption of APC function can promote
tumor formation, various possible mechanisms have been proposed. One of these
hypotheses suggests that tumor formation is the result of haploinsufficiency, a threshold
effect involving the deficiency of APC gene product (51). For example, the normal
homozygote wild type produces enough of the APC gene product so that random
fluctuations of its concentration never, or at least only very rarely, go below a threshold
that permits localized excessive growth. The deficient heterozygote, however, may allow
random fluctuations in the level of the APC gene product to go below this threshold
relatively frequently. In those area of the colon where this happens, excessive epithelial
growth may be initiated, giving rise to polyps. In a related hypothesis, APC is a recessive
tumor suppressor gene and inactivation of both alleles is necessary for the cancer to
develop. This is also known as the ''two-hit" hypothesis (67, 68). That occurrence of
somatic APC mutations in early adenomas from FAP patients supports this view (69, 70).
In the other hypothesis, chain-terminating mutations in APC result in truncated
polypeptides which can inhibit the normal function of the APC gene product in a dominant
negative fashion. The great majority of APC mutations described to date result in stable
>80 kDa truncated proteins, supporting this scenario ( 57). Further subcellular localization
has demonstrated that wild type APC binds to microtubules and may be important in their
formation (63, 64). However, mutant APC product (missing the carboxyl terminal part of
the molecule as a result of premature truncation) appears to lack this ability (63). Other
intriguing possibilities have been raised by the recent discovery that APC may be an
important molecule in regulating cell adhesion. This hypothesis is based primarily on
13

evidence that APC can bind to and regulate P-catenin (60, 61, 7 1-7 3). P-catenin is one
member of a family of intracellular catenins that regulate cell-cell adhesion between
epithelial cells, in part through interactions with E-cadherin (74-76). Immunoprecipitation
experiments have demonstrated that three imperfect 15 amino acids repeats located
between residues 1020 and 1169 of APC are involved in a constitutive binding interaction
with P-catenin in human cells (Figure 2.2) (60, 61). APC can trigger a post-translational
down-regulation of P-catenin that appears to be mediated by binding of P-catenin to a
second region of APC (71). This binding domain consists of several 20 amino acid repeats
located between amino acids 1342 and 2075 of APC (60, 71). APC mediated regulation
of P-catenin levels may be further controlled by activation ofWntl (the analogous
molecule of Wingless (WG) in mice, where WG is a cell to cell signal in the fruit fly
Drosophila that triggers many key developmental processes) and glycogen synthase kinase
3P (GSK 3P) (77, 78). These findings have led to a tentative model implicating APC in a
Wntl signal transduction cascade (Figure 2.3) (72, 77, 78). In the absence ofW nt signals,
APC simultaneously interacts with the serine kinase GSK 3 P and P-catenin.
Phosphorylation of APC by GSK 3 P regulates the interaction of APC with P-catenin,
which in turn may regulate the signaling function of P-catenin (78). Wnt signaling appears
to antagonize GSK 3P activity. Upon Wnt signaling, P-catenin is stabilized and exists
primarily as a cytoplasmic monomer (77). However, since Wnt1 does not appear to be
expressed in the intestine, it is unclear whether this pathway is fundamentally important in
regulating intestinal tumorigenesis.
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Figure 2. 3.

Potential role of APC in a Wntl signal transduction pathway. The
interactions between APC, P-catenin, and E-cadherin as well as the
potential regulation of these interactions by GSK 3P and Wntl are shown.
In the absence ofWntl, GSK 3P is postulated to be active. GSK 3P
phosphorylation of APC enhances binding of P-catenin to the 20 aa repeats
located between amino acids 1342 and 2075 of APC. Binding in this
region of APC leads to P-catenin degradation. P-catenin also binds
constitutively to the 15 aa repeats located between 1020 and 1169 of APC.
Wntl activity is believed to reduce GSK 3P activity. Under these
conditions P-catenin does not bind to the 20 aa repeats of APC, and
therefore P-catenin degradation is prevented. Thus, intracellular levels of
P-catenin increase. Note that P-catenin can still binds in the 15 aa repeat
region of APC. (Ref 79)
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Taken together, the following summarizes the important features of the APC
mutation:
1.

Mutations of the APC gene are found in DNA isolated from sporadic
tumors of digestive organs as well as in constitutional DNA of FAP
patients.

2.

Inactivation of both alleles of APC is required for development of most
tumors in the colon and rectum.

3.

The great majority of known mutations would result in truncation of the
APC gene product.

4.

Almost all known mutations are located within in the 5' (proximal) segment
of the coding region in exon 15, although somatic mutations in colorectal
tumors tend to cluster in the mutation cluster region (MCR) located
between codons 1286 and 1513.

5.

Most point mutations in APC are transitions from cytosine to other
nucleotides.

6.

The protein products of mutant of APC genes are defective in their ability
to stimulate degradation and maintain low levels of cytoplasmic �-catenin.

7.

Truncating mutations in amino terminus of APC are associated with a low
penetrance in which patients develop a relatively small number of polyps.

8.

Disruptions of APC between codons 1250 and 1464 or in carboxyl
terminus region are associated with an increased number of colorectal
tumors.
16

Familial adenomatous polyposis (FAP)

The original report ofFAP is attributed to Cripps (80), who described the cases of
a brother and sister whose rectums were thickly studded with 'several mulberry-looking
masses of growth, varying in size from a small pea to a good sized nut'. Five years later,
Smith (8 1) reported the presence of multiple polyps in three siblings and recognized the
high risk of colorectal cancer associated with this condition. Subsequently, FAP was
acknowledged to be transmitted as an autosomal dominant inherited condition with a high
degree (>95%) of penetrance. W ithin the last decade, the molecular pathogenesis of FAP
has been elucidated where the genetic linkage of FAP and APC has been located to a
small region of the long arm of chromosome 5 ( 43, 45, 46, 49-52). Over 200 germline
mutations of this very large APC gene have been described and most are predicted to
result in a truncated protein that is dysfunctional in its role as a tumor suppressor.
It is well understood to date that familial adenomatous polyposis (FAP), in which
affected individuals develop hundreds to thousands of colorectal adenomas (also called
adenomatous polyps) during the second and third decades of life, is an autosomal
dominant inherited human cancer disease that affects about 1 in 7000 individuals and is
caused by a germline mutation ofthe APC gene (44-46, 51). These adenomas are not
initially malignant, but if not removed, some are likely to give rise to adenocarcinoma.
Indeed, adenomas have been suggested to be precancerous states for most colorectal
tumors (8 2). Additionally, FAP patients often develop extracolonic manifestations,
including retinal lesions, osteomas, desmoids of the skin, and brain tumors. The majority
of the patients with FAP possess detectable mutations of the APC gene (24). The
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detection of mutations is difficult because they usually involve small insertions, deletions,
or changes in single base pairs, resulting in a truncated protein product ( 44). Genetic
testing is now available for FAP through the use of DNA markers with a 99% accuracy.
Unfortunately, this requires a previous specific diagnosis of FAP in two family members.
Because each FAP family may have a different mutation, developing a screening test for
individuals without a family history has proven difficult (8 3).
Another general principle illustrated by FAP concerns the complex relationship
between genotype and phenotype. FAP patients do not develop uniform clinical features,
despite the fact that all have mutations of the same gene and virtually all mutations result
in C-terminal truncated proteins (56). In some cases, the difference in phenotype is due to
the type of mutation. For example, retinal lesions (congenital hypertrophy of the retinal
pigment epithelium, called CHRPE) are associated with truncating mutations between
codons 463 and 1387 (Figure 2. 2) (84). Truncating mutations N-terminal to codon 157
are associated with an attenuated form of FAP in which patients develop a relatively small
number of polyps (Figure 2. 2) (85). Some studies have suggested that mutations between
codons 1250 and 1464 are associated with an increased number of colorectal tumors (53).
On the other hand, patients with identical mutations can develop dissimilar clinical
features. For example, some patients with identical truncating mutations develop features
of Gardner's syndrome (mandibular osteomas and desmoid tumors) while others do not
(46). The complex relationship between genotype and phenotype is also apparent in other
hereditary cancer predisposition syndromes, including those associated with breast cancer
(86). Whether these phenotypic difference result from environmental influences or
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modifying genes is not known.
A compelling example of the relationship between phenotype and APC genotype
is observed in Min mice. These mice develop multiple intestinal adenomas and have a
truncating mutation of the murine Ape gene at a position similar to that found in many
FAP patients (1 7).
Minl+ mouse
Contemporaneous with the search for the APC gene, a strain of mice containing
multiple intestinal adenomas was developed following an ethylnitrosouria (ENU)-induced
germline mutation of a C57BL/6J male mouse in 1990 (18, 87). Sequence analysis of the
entire 8535 bp Ape cDNA identified that this model, the multiple intestinal neoplasia
(MIN) mouse, has a fully penetrant dominant phenotype with a germline nonsense
mutation (leu (TIG) � stop (TAG) transversion at nucleotide 2549, codon 850) in the
murine homologue of the APC gene (Ape) (17). This mutation is analogous to those
found in human FAP, in sporadic colorectal cancers and in hereditary nonpolyposis colon
cancer (HNPCC) (23, 24, 88-90). Homozygous MinMin mice are embryonic lethal, but
heterozygotes (Mini+) on a C57BL/6J background mice develop numerous adenomatous
polyps throughout the entire length of the intestinal tract within the first 3 months of life
and rarely live past 150 days of age (18). Since all intestinal tumors in B6 Min/+ mice are
benign adenomas, the premature death of these animals is associated with secondary
effects of tumor growth, including morbidly chronic anemia (18).
The human and mouse APC/Ape genes are 86 and 90% identical at the nucleotide
and amino acid levels, respectively (17). The Mini+ mouse has a nonsense mutation at
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codon 850 of Ape. The protein product of the Ape Min allele would contain the
homodimerization domain as well as the central repeat region but would lack all other
known APC binding domains. A comparison of the phenotypes associated with
heterozygosity for germline mutations in APCIApe for humans and Min mice is illustrated
in Table 2. 2.
The number of intestinal tumors and lifespan in Mini+ mice were strongly affected
by genetic background. For example, the Mini+ F1 progeny crossed with AKR strain
(AKR/J x C57BL/6J) F 1 mice average 6.0±4. 7 intestinal tumors per mouse and can live
beyond 300 days. This change represents a significant decrease in tumor number from the
average of approximately 30 tumors seen in Mini+ mice derived from C57BL/6J
background ( 18, 87). Similar results were found in F 1 progeny with two other mouse
strains, MA and CAST (87). This finding suggested that the � MA and CAST strains
may carry genetic modifiers that act dominantly or semi-dominantly to reduce tumor
number in Mini+ mice. In 1993, linkage analysis demonstrated that a single locus,
designed as Mom-I (for modifier ofMin-1) in a region similar to a segment of human
chromosome 1 that was mapped to a 15-cM region on mouse distal chromosome 4
accounts for much of this difference between strains (91). Thus, Mom-I seems to play an
inhibitory role in the formation of polyps in the MIN mouse. Recently, MacPhee et al.
(92) reported that a secretory phospholipase A2 was an attractive candidate gene for the
Mom-1 locus. This gene pla2s is mapped to the same region (distal chromosome 4) that
contains Mom-I and MIN mouse strains with higher pla2s expression develop fewer
polyps.
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Table 2. 2.

Comparison of phenotypes for mice and human with
germline Ape / APC mutations§

Mouse (Mini+)

Established from an END-treated
C57BL/6J male mouse and is
associated with a defect in the
APC gene resulted in a dominant
nonsense mutation in the codon
850 of mouse Ape gene

Human

Autosomal, dominant inherited disease

Affects 1 in 7000 individuals

Mouse Ape gene mapped to
chromosome 18

APC gene mapped to chromosome 5q2 1

Multiple colon adenomas

Multiple colon adenomas
( 100- 1OOOs)

Small intestinal adenomas
> 90% adenomas were found
in small intestine
(30-50 tumors/mouse)

Cystic intestinal crypts
Epidermoid cysts
Desmoid tumors
Mammary adenoacanthoma

§

Small intestinal adenomas
Develop carcinomas from adenomas
following a second mutation
(i.e., p53, k-ras)
Epidermoid cysts
Desmoid tumors
Gastric polyps
Osteomasof skull and mandible
Hypertrophy of retinal pigment
epithelium
Abnormal dentition
Lipomas

Modified from Ref 79
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The Mini+ mouse model is currently being used in cancer research because of
close similarities at the genotypic and phenotypic levels with human FAP. This was the
first spontaneous murine intestinal tumor model and provides an excellent experimental
tool for addressing many fundamental questions associated with intestinal neoplasia.

ENVIRONMENTAL FACTORS IN COLON CARCINOGENESIS
Colorectal cancer is very common in North America, Western Europe, Australia,
and New Zealand, whereas the age-standardized incidence rate of colorectal carcinoma is
very low in developing countries such as India and Africa (20, 2 1). Observations on
migrants to the United States from Japan, comparing cause-specific mortality rates in 1949
to 1952 with 1959 to 1962, show that the mortality rates of colon cancer among Japanese
males have risen in one decade almost to equal the higher risks prevailing for United
States caucasians (93). A similar trend was seen among Polish and Chinese immigrants to
the United States (94) and among Polish and South East Asian immigrants to Australia
(95).
Marked international differences in the incidence and mortality of colon cancer and
increase of risk in populations migrating from low to high risk areas suggest that
environmental factors, specifically dietary factors play an important role in the etiology of
colon cancer. For example, the etiological studies indicate strongly that diets rich in fat,
meat and animal proteins and low in fiber, fruits and vegetables are causally related to the
risk of colon cancer. Gregor et al. demonstrated that colon cancer risk in populations was
more strongly correlated with current diet than with the diet consumed 20 years
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previously, suggesting that dietary fat/meat is more important at late promotional or
progression stages than at the initiation stage (96). Similar studies of migrants showed
that the risk of colorectal cancer was correlated with the diet of the current residence
rather than the place of birth.
Dietary fat and colon cancer

Dietary fat has received considerable attention as a risk factor in the etiology of
colon cancer (4, 97, 98). Several animal model studies have provided evidence that the
fatty acid composition of dietary fat is one of the determining factors in colon
carcinogenesis in which fatty acids are thought to play an important role in both the
development and prevention of colorectal cancer (97, 99-102). Saturated and n-6
polyunsaturated fatty acids promote colon cancer in a laboratory animal model (103-109).
On the other hand, accumulating evidence suggests that n-3 PUFAs, particular
eicosapentaenoic acid (EPA, 20: Sn-3) and docosahexaenoic acid (DHA, 22: 6n-3), found
in fish oil, inhibit cancer formation (4, 107-115). Consumption of fish appears to protect
against colon cancer in human (116-118). Although the mechanism(s) of colon tumor
promoting/suppressing effect of dietary fatty acids is not precisely understood, the
modulation of colon tumors by dietary fat is thought to be mediated, in part, through
alterations of membrane phospholipids and eicosanoid biosynthesis (4, 109).
n-3 polyunsaturated fatty acids

Marine fish oils are rich sources of unsaturated fatty acids differing in chemical
structure from comparable polyunsaturated lipids in plants. Two of the most well known
marine fatty acids are EPA and DHA. Chemists have called the polyunsaturated fatty
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acids in fish oil n-3 ( or omega-3) fatty acids, because they have a characteristic double
bond 3 carbons from the methyl end of the molecule. Structurally they differ from n-6
polyunsaturated fatty acids found predominantly in plant oils because the first double bond
in these fatty acids is located 6 carbons from the methyl end of the molecule ( 119).
The biological properties of fish oils center around their ability to reduce the
synthesis of prostaglandins and leukotrienes generated from the metabolism of arachidonic
acid, arguably the most important n-6 polyunsaturated fatty acid associated with
membrane phospholipids ( 120). Fish oils, by suppressing the formation of these agents,
have anti-inflammatory properties and have been investigated in animals for cancer
preventive effects. In tumorigenesis studies, fish oil diets reduce the incidence of
chemically-induced focal areas of dysplasia and colonic tumors in rodents ( 111, 112, 12 1).
In a study with spontaneous intestinal tumor model, Mini+ mice, Paulsen et al.
demonstrated that long-term (up to 18 weeks) dietary treatment with K85, a fish oil
derived concentrate enriched in EPA and DHA, suppressed the formation and growth of
small intestinal tumors ( 122). This finding is similar to the antitumor effect of dietary
DHA in the Ap�716 knockout mouse, a model characterized by 1OOs of intestinal tumors
( 123).
The inhibition of prostaglandin release may explain in part the beneficial effect of
fish oil in controlling proliferation (112, 124). Prostaglandins appear to enhance
carcinogenesis ( 125) and modulate proliferative activity in rat colonic epithelium ( 126),
although their major effect may not be on proliferation per se but rather to slow migration
and retard senescence ( 127, 128), thus prolonging cell life and delaying loss of epithelial
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cells. Inhibition ofprostaglandins by fish oil could accelerate cell loss, thereby reducing
exposure of senescent cells to carcinogenic transformation .
n-6 polyunsaturated fatty acids

Linoleic acid (LA , 18:2 n-6) is the most commonly consumed PUFA in the
American diet and is the parent compound (metabolic precursor) of the n-6 family of
PUFA that includes arachidonic acid ( A A). The origin of tissue A A is LA when LA is the
only n-6 PUF A in the diet. A number of cancers, including those of the intestines, have
been strongly linked to the amount of LA in the diet (97, 129-131). Increasing the amount
of LA in the diet of rodents enhances the growth of chemically-induced colon, breast and
pancreatic tumors (97, 132-134). The mechanisms responsible for LA 's effects are
uncertain, but because LA is the biological precursor of A A and eicosanoids, a commonly
proposed hypothesis suggests that LA mediates its effects through A A . A A content in
colonic mucosal phospholipids is associated with higher indices of cell proliferation (135)
and tissue A A content is significantly correlated with eicosanoid biosynthesis (136).
However, despite these relationships the mechanism of action by LA is still unclear
because its conversion to AA and subsequently to eicosanoids is highly regulated ( 137).
In fact, if the diet already contains sufficient levels of LA (i.e., 3% of energy), increasing
consumption has little effect on either tissue A A content or eicosanoid biosynthesis (137).
Eicosanoids

Eicosanoids are oxygenated derivatives of 20-carbon polyunsaturated fatty acids.
Among these, arachidonic acid is the preferred precursor from which most metabolic
pathways have been described. Arachidonic acid is released from the sn-2 position of
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membrane phospholipids by phospholipases, A2, C and D mediated pathways ( 138). Of
the various phospholipases, PLA2s which directly cleave fatty acids from the sn-2 position
are considered the most important ( 139). Once arachidonic acid is released, it is further
metabolized to eicosanoids via one of three pathways. Eicosanoids are biologically active
regulators with a wide range of physiological functions such as lymphocyte and platelet
activation/aggregation, vasodilation, vasoconstriction, regulation of blood pressure, blood
clotting, the immune system and modulation of the reproductive system to name a few.
They are also involved in pathological processes such as inflammation, allergies and
certain cancers ( 140-142). Eicosanoid production can be regulated by dietary fats. For
example, animals consuming the n-3 PUFA produce less prostaglandins, while low to
moderate levels of arachidonic acid (AA, 20: 4n-6) augment eicosanoid production ( 136,
137, 143-146).
The eicosanoids, consisting of prostaglandins and thromboxanes, are one set of
bioactive products of arachidonic acid metabolism. Arachidonic acid can be metabolized
via three major pathways: a) the epoxygenase pathway produces epoxy and dihydroxy
acids, b) the lipoxygenase pathway produces leukotrienes, lipoxens and hydroxy acids, and
c) the cyclooxygenase pathway results in prostaglandins and thromboxanes ( 138).
Collectively all of these oxidized products are known as eicosanoids. They are
biologically active compounds, each with a diverse set of highly specific physiologic
actions, some of which are in opposition to the actions of other eicosanoids. For example,
prostaglandin E2 (PGE2) has vasodilatory and bronchodilatory properties while the
leukotrienes, LTC4, LTD4, and LTE4 have broncoconstrictive and vasoconstrictive
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properties ( 147). These are products from different pathways usually in different cells and
a balance is necessary for the homeostasis of airway openings and of vascular tone.
Thromboxane A2 (TXA2) produced by platelets stimulates their aggregation while
prostacyclin (PGI2) produced by the endothelial cells, inhibits this aggregation ( 147).
These products, both from the cyclooxygenase pathway, are produced by different cells
and help maintain a coagulation balance in the blood. It is evident that the achievement of
the necessary balance for homeostatic function requires that these molecules and their
functions must be carefully regulated. This regulation is achieved by the cells responding
to highly specific stimuli which arise from cell-cell interactions, receptor-mediated contact
with secreted soluble molecules, or even physical stresses such hypoxia or shearing forces
( 138).
There are two key regulatory points for eicosanoid synthesis ( 148). The first is the
liberation of free arachidonic acid from the glycerylphospholipids in cellular membranes.
Major donors for arachidonic acid formation include phosphatidylinositol and
phosphatidylcholine. Phosphatidylinositol can be cleaved to liberate arachidonate either by
the sequential actions of phospholipase C, diacylglycerol lipase, and monoacylglycerol
lipase, or directly by the action of phospholipase A2 . Arachidonic acid is cleaved from
phosphatidylcholine via phospholipase A2 . Quantitatively, PLA2 action is considered to be
the more significant contributor of arachidonic acid release in most cell types. This step is
considered the rate limiting step for prostaglandin formation (149).
The second point of regulation is the first committed step of prostanoid
production, the conversion of arachidonic acid into PGH2 by prostaglandin G/H synthase
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(PGHS), commonly known as cyclooxygenase. This reaction encompasses two steps, first
a bis-oxygenase activity catalyses conversion of arachidonic acid to PGG2 then a
peroxidase activity reduces the 15-hydroperoxyl group of PGG2 producing PGH2 . Both
the bis-oxygenase (or cyclooxygenase, hence the PGHS common name) and peroxidase
activities are accomplished by the same protein that has two different, albeit interacting
active sites ( 150, 151). The ability to separate these two activities is demonstrated by a
phenylalanine substitution of Tyr 3 85 which eliminates the oxygenase activity but not the
peroxidase activity ( 152) and by aspirin inhibition which eliminates cyclooxygenase
activity but not the peroxidase activity ( 153). In addition, PGHS is considered a suicide
enzyme since it inactivates itself during catalysis (154). Details of the enzymatic reactions
are reviewed by Smith, Marnett, and DeWitt ( 138). PGHS is an integral glycoprotein with
an associated heme group required for both activities ( 155). It has been localized to the
endoplasmic reticulum and nuclear membrane ( 156) and appears to function as a
homodimer ( 151).
The last step in the production of the variety of prostaglandins and thromboxanes
in a given cell is accomplished by the rapid isomerization of PGH2 by a panel of
isomerases specific for a given cell type yielding PGD2, PGE2, PGF2, PGI2 or TXA2
depending on the cell type ( 148). PGH2 is very unstable and will nonenzymatically
convert to the PGE series if not acted on enzymatically ( 157). The profile of eicosanoid
products produced reflects the complement of these isomerases present in a given cell
type. However, the amount of product produced reflects both the availability of
arachidonate as substrate and the amount of active PGHS. Beyond providing cell product
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specificity, there is little evidence suggesting the isomerases are significant regulatory
points in eicosanoid synthesis. Albeit, there are reports in endothelial cells and murine
3T3 cells that PGI synthase can be co-regulated with PGHS ( 158, 159).
Eicosanoids and cancer
The role of eicosanoids in the development of colon cancer and their regulation of
tumor growth and metabolism has received much attention. The evidence that eicosanoids
may be involved in the pathogenesis of colon cancer is mainly based on the following two
sets of findings. First, the metabolism of arachidonic acid is altered in human colon
cancer, carcinogen-induced animal models and cancer cell lines. For example, the
prostaglandin levels are higher in tumor cell lines ( 160) and in intestinal tumors compared
to normal mucosa ( 16 1), and the activity of cyclooxygenase (the rate limiting enzyme for
eicosanoid biosynthesis) is enhanced during colonic carcinogenesis ( 162-164). Venous
blood draining colon tumors contains large amounts of PGE2 ; the larger the tumor the
higher PGE2 output ( 165). The second group of findings results from the ability of
NSAIDs to protect experimental animals and humans from colon cancer (3, 12, 166-170).
Since NSAIDs are the best known inhibitors of PG synthesis, the commonly proposed
hypothesis is that their effect on colon cancer is brought about via inhibition of PG
synthesis ( 171), and that, in turn, PGs are crucial in the pathogenesis of colon cancer.

PROSTAGLANDIN H SYNTHASE (PGHS; CYCLOOXYGENASE, COX)
Prostaglandin H synthase (PGHS), which is also referred to as cyclooxygenase
(COX) is considered a key enzyme physiologically because it catalyzes the oxygenation
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and endoperoxide reduction reactions required for the biosynthesis of prostaglandins and
thromboxanes from arachidonic acid ( 148). These potent biological signaling molecules
mediated a multitude of diverse biological functions such as inflammation, immune
response, platelet functions, blood pressure, reproduction and cell proliferation or
differentiation ( 172). Each of these functions may be regulated through several pathways,
collaboratively mediated by prostaglandins.
PGHS is a dimeric enzyme consisting of identical 70-72 kDa subunits ( 148).
PGHS is an integral membrane glycoprotein found primarily in the intraluminal
compartment of endoplasmic reticulum and nuclear envelop . It contains two catalytic
activities; a cyclooxygenase activity that adds two molecules of 02 to arachidonic acid
(A A ), forming the hydroperoxy arachidonate, PGG2; and a peroxidase activity that
reduces PGG2 to the endoperoxide, PGH2 ( 148, 172). Each 70 kDa subunit requires one
molecule of bound heme for maximal activities of both kinds ( 173). The cyclooxygenase
and peroxidase active sites are separate on the protein molecule, thus the effect of aspirin
and other NSA IDs are modulated through the inhibition of cyclooxygenase activity but
occur without affecting peroxidase ( 174, 175).
Two forms of cyclooxygenase are known to be present in eukaryotic organisms: a
COX- I first purified from ram seminal vesicles encoded by a 2 .8-kilobase mRN� and a
newly discovered mitogen-inducible COX-2 encoded by a 4-kilobase mRNA ( 176).
COX- I was initially characterized, purified and cloned from sheep seminal vesicles ( 150,
177, 178) and is 90% homologous at the amino acid sequence level in murine, rat and
human ( 139). COX- I is expressed constitutively in almost all cell lines and virtually all
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mammalian tissues and can therefore produce prostaglandins in immediate response to
hormones. ( 148, 179). Tissues that express high levels of COX-I include platelets,
endothelial cells, stomach, kidney, and smooth muscles ( 138, 148). COX-I is believed to
be responsible for normal cellular homeostasis or "housekeeping functions" such as
platelet aggregation, anti-aggregation by endothelial cells, blood pressure regulation ( 172).
In 1989, Simmons et al. ( 180) identified a second, inducible form of cyclooxygenase,
known as prostaglandin endoperoxide synthase-2 (COX-2). This cyclooxygenase isoform
was independently identified by differential screening of a phorbol ester-stimulated Swiss3 T3 fibroblast cDNA library ( 18 1). Unlike COX-I, COX-2 is virtually undetectable in
most cell types under normal physiological conditions, but its expression can be rapidly
induced by a wide range of extracellular and intracellular stimuli, including
lipopolysaccharide ( 176, 182, 18 3), forskolin ( 184), interleukin-I (IL-I), tumor necrosis
factor (TNF) ( 185, 186), serum (187, 188), epidermal growth factor (EGF) ( 189),
transforming growth factor-a (TGF-a) ( 190), platelet activating factor, retinoic acid
( 191), and endothelin ( 192). Additionally, the formation of COX-2 protein parallels the
increase in eicosanoid production that is commonly the result of mitogenic stimulation in a
wide variety of cell types. For example, prostaglandin production increases rapidly in rat
intestinal epithelial cells (RIE) after stimulation with mitogens such as TGF-a or EGF
( 190). In resting unstimulated macrophages, only COX-I but not COX-2 was detected
(176), hence prostaglandins are not being produced by this enzyme (COX-2).
The genomic structure of both human and murine COX-I is composed of 11 exons
and 10 introns spanning 22.5 kb (Figure 2. 4) ( 193-195). The human COX-I locus maps
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Gene structure of human COX- I and COX-2 (Ref. 1 95)

to chromosome 9q 32-q3 3.3 (193). Although COX-1 and COX-2 proteins are similar in
size (70-72 k.Da), the human COX-2 gene is only 8.3 kb in size. This reduction in size is
primarily due to smaller introns as well as exon 2 is absence in COX-2 (Figure 2.4).
Fluorescence in situ hybridization localized human COX-2 to chromosome lq25.2-q25.3
( 196).
COX-1 mRNA encodes a 565-residue, 70 k.Da protein containing a short signal
peptide and four possible N-linked glycosylation sites (Figure 2.5). COX-2, a roughly 70
k.Da protein, is -- 75% homologous to the COX-I protein. At the protein level, major
domains such as the serine acetylation site, the cyclooxygenase and peroxidase regions are
conserved between the two isoforms; however, there are some other differences in the
primary amino acid sequence. COX-I contains a 26 amino acid leader sequence in the
amino terminus while COX-2 contains a shorter, nonhomologous 17 amino acid leader
sequence (Figure 2.5) ( 197). COX-2 possesses an 18 residue insert at the carboxyl
terminus that is absent from COX-I ( 139, 184). It is possible that these subtle differences
in the primary amino acid sequence may cause differences in the secondary and tertiary
structure of the protein that could affect the active site of these two enzymes. For
example, COX-1 is completely inhibited by aspirin treatment, whereas COX-2 converts
arachidonic acid to 15-R-HETE after aspirin treatment, functioning as a 15-lipoxygenase
( 198, 199). In addition, these differences at the NH2 terminal and COOR terminal of these
isoforms may affect their subcellular localization or stabilities of the two proteins. Each
protein is localized predominantly in the endoplasmic reticulum (ER) and nuclear envelope
(NE) when examined by immunocytofluorescence using isozyme specific antibodies (200).
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COX-I immunoreactivity was equally distributed between the ER and NE whereas COX2 immunoreactivity was twice as concentrated in the NE as in the ER. Additionally,
histochemical staining for enzyme activity has shown that COX-I functions predominantly
in the ER whereas COX-2 is active in both the ER and NE (201). These differing
subcellular locations support the emerging view that COX-I and COX-2 represent two
independently operating eicosanoid biosynthesis systems. COX-I produces prostaglandins
that mediate housekeeping functions while eicosanoid products produced via COX-2
could mediate inflammation and could be preferentially distributed to the nuclear
compartment of the cell and therefore may modulate intranuclear differentiation /
proliferative functions and transcription of target genes.
COX-1 and COX-2 knockout mice
Gene disruption techniques have recently been utilized to understand the biological
relevance of a variety of regulatory molecules including enzymes, cytokines, growth
factors, transcription factors, and cell surface receptors. Important to COX research was
the successful generation (by targeted gene disruption) of COX- 1 and COX-2 deficient
mice (202-204). COX-I knock out mice survive as well as wild type animals, have no
gastric pathology, and show less indomethacin-induced gastric ulceration than wild type
mice. They also show reduced platelet aggregation and a decreased inflammatory
response to arachidonic acid, but not to phorbol ester stimulation.
COX-2 null mice show no inbred gastrointestinal pathology, but their kidneys
exhibit progressive deterioration during aging. Their inflammatory responses to phorbol
ester and arachidonic acid do not differ from wild type mice and they have a normal
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inflammatory response to bacterial invasion of the peritoneum.
These sets of observations suggest the need to evaluate the current view
concerning the detailed functions of COX isoforms, for example, that prostaglandins
produced from COX- I protect against stomach ulceration and that the inflammatory
response is due to prostaglandins produced by COX-2. Clearly, the knockout mice will
continue to be of great value for the study of the precise roles of the two isoforms of COX
and to aid in the development of novel NSAIDs.
Role of cyclooxygenase in cancer

A role for cyclooxygenase in carcinogenesis has been demonstrated in
epidemiological studies in which mortality from colorectal cancer was reduced
approximately 40-50% in individuals taking aspirin (9, 11, 205). In a related finding,
sulindac treatment reduced the size and number of rectal polyps in patients with FAP ( 13).
When sulindac administration was discontinued, the tumors recurred. If treatment was
resumed, the tumors regressed again (206). In rat and mouse model of colon
carcinogenesis, NSAIDs including indomethacin, piroxicam and sulindac have had
chemopreventive effect as judged by a reduction in the number of tumors per animal ( 15,
171, 207). The apparent mechanism for the clinical and experimental effects ofNSAIDs is
inhibition of COX and subsequent reduction in the levels of prostaglandins. The molecular
basis for the beneficial effects ofNSAIDs in cancer is little understood and complicated by
the multistage nature of the disease.
The relative contributions of the COX-I and COX-2 isozymes to carcinogenesis is
not known and has only recently become an intense area of investigation. COX-2 appears
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to be the isoform responsible for elevated prostaglandin production in neoplastic cells.
The mRNA of COX-2 but not COX-I was markedly elevated in colorectal
adenocarcinomas and a subgroup of colonic adenomas as compared with levels in adjacent
normal tissues, this may indicate that increased expression of COX-2 is involved in the
progression to a transformed state (208). Enhanced COX-2 expression was also observed
in patients clinically diagnosed with colorectal cancer (208-2 10). In mouse skin tumor
models, COX-2 protein was constitutively overexpressed in carcinomas (211). On the
other hand, COX-I expression remained comparable in tumors and normal appearing
tissue in those studies. In general, the extent and intensity of immunoreactive COX-2 in
cancer cells is much greater than that of other cell types. In contrast, the expression of
COX-I is weak in both normal and cancerous specimens. These data suggest that
increased prostaglandin production in colon cancer tissues may be due to enhanced
expression of COX-2. Furthermore, selective inhibition of COX-2 may prove to be more
efficacious in the retardation of colon cancer cell development. These observation also
suggest that beneficial effect ofNSAID treatment against colon cancer may be mediated
by inhibition of COX-2. In addition, COX-2 is found predominantly in the nuclear
envelope and COX-I in ER, suggesting that the two enzymes represent separate signaling
systems. The nuclear localization of COX-2 and its inducibility in response to mitogenic
stimuli link it to proliferation.

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are common anti-inflammatory
37

therapeutic agents. In 1986, more than 100 million prescriptions were written for these
drugs (212). During the past 30 years, there has been a substantial increase the number of
NSAIDs. In the United Sates, salicylates were the most common treatment for rheumatic
disease (2 13) and 14 NSAIDs are now available. As a group, NSAIDs have anti
inflammatory, analgestic, antipyretic and platelet-inhibitory actions, though they certainly
do differ chemically and pharmacokinetically.
NSAIDs currently available come from a variety of chemical classes (Table 2. 3).
Their physicochemical properties determine their distribution in the body, and thus
differences in these properties may lead to variable therapeutic performance (2 14).
NSAIDs are a family of pharmacological compounds whose major mechanism of
action is inhibition of cyclooxygenase (6). Since 1991, several reports indicate an
association between an intake of NSAIDs and a decreased risk for developing colorectal
cancer. Three independent lines of research indicate an inverse correlation between
NSAIDs use and colorectal carcinogenesis. First, most epidemiological studies show a
40-50% reduction in mortality and the relative risk of colorectal cancer in individuals who
regularly consume NSAIDs (like aspirin) compared with those not taking these agents.
Second, the NSAID sulindac has been shown to significantly reduce the number and size
of adenomatous polyps in patients with familial adenomatous polyposis (FAP). Third, in
line with the findings in humans, animal models of colorectal carcinogenesis studies have
demonstrated that several different NSAIDs provide chemoprotective effects against colon
carcinogenesis as shown by a reduction in the tumor load and size.
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Table 2. 3.

Chemical classification of NSAIDs§

Carboxylic acids
Acetylated ------ aspirin*
Nonacetylated ------ choline salicylate, diflunisal, magnesium salicylate, salicylamide,
salicylate with magnesium salicylate, salsalate, and sodium salicylate
Acetic acids ------ diclofenac*, indomethacin*, tolmetin*, sulindac*, and etodolac*
Propionic acids ------ ibuprofen*, naproxen *, fenoprofen *, pirprofen, indoprofen,
tiaprofenic acid, oxaprozin, ketoprofen *, fenbufen, flurbiprofen, carprofen, and
suprofen
Fenamic acids ------ flufenamic acid, mefenamic acid*, meclofenamic acid*, and niflumic
acid
Enolic acids ------ oxyphenbutazone, phenylbutazone*, piroxicam *, sudoxicam,
tenoxicam, and isoxicam
Nonacidic compounds ------ nabumetone, proquazone, and bufexamac
Modified from Ref. 2 14
* Available in the United States

§
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Epidemiological studies of NSAIDs and colorectal cancer

There have been a number of observational retrospective and case control studies
on the relationship of intake of aspirin or other NSAIDs and the subsequent risk of
developing colorectal cancer (9, 11, 205, 2 15-22 1). These studies are summarized in
Table 2. 4. All of these studies have been consistent and demonstrated a protective effect
of NSAIDs; an approximately 50% decreased risk of colorectal cancer is noted in groups
taking NSAIDs, primarily aspirin.
Many but not all prospective cohort studies examining the effect of aspirin on the
incidence or mortality of colon cancer indicated a protective effect (Table 2.5) ( 11, 220224). Thun and colleagues ( 11) reported the results of the largest and most frequently
cited study of the relationship between aspirin use and colon cancer. They conducted a
cohort of over a million volunteers and family members with a questionnaire on cancer
risk and personal health habits, including medication use. Complete information was
available for over 660,000 persons for the 6-year study period. Death rates from
colorectal cancer decreased with more frequent aspirin use. The relative risk for fatal
colorectal cancer among persons using aspirin every other day or more a month was O.60
in men and O.58 in women. In a subsequent report, Thun and associates evaluated aspirin
use and the risk of any fatal cancers (223). Mortality rate decreased with more frequent
aspirin use for cancers of the oesophagus, stomach, colon and rectum. On the other hand,
some studies suggested that the use of aspirin, at a dose adequate to prevent myocardial
infarction, was not associated with protection against colorectal cancer (225, 226).
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Table 2.4.

Summary of retrospective case control studies of NSAIDs use and colorectal cancer incidence
End Point

NSAID
Dose

Authors

Setting

Study Size

Kune et al.
( 1 988)

Population based

Colorectal cancer
7 1 5 cases
727 controls (incidence)

Aspirin
daily
NSAIDs
daily

0.60
Adjusted for age, sex,
(0.40-0. 82) diet and physical
0.77
activity ( community
(0.60- 1 .0 1 ) controls)

1 326 cases Colorectal cancer
489 1 controls (incidence)

Aspirin
� 4 days/week
� 3 months

0. 5
(0.40-0. 80)

Adjusted for age, sex,
race, religion, physical
activity, family history,
and educational level
( cancer and noncancer
controls)

0.49
(0.3-0.8)
0.66
(0.4- 1 . 1 )

vs. negative controls
for fecal blood
vs. positive controls
for occult blood

Hospital based
Rosenberg
et al. ( 1 99 1 )

Results
Relative Risk

�
,__.

Logan et al.
( 1 993)

Colorectal adenomas NSAIDs
Community based 1 47 cases
any use
15 3 controls

Comments

Table 2.4.

(Continued)
End Point

Authors

Setting

Study Size

Suh et al.
( 1993)

Hospital based

Colorectal cancer
830 cases
Polyps
212 cases
1662 controls

NSAID
Dose

Results
Relative Risk

Aspirin
< 1 day/week
1-2 days/week
> 2 days/week

.,I:::..

Peleg et al.
( 1994)

Adjusted for age, sex,
0. 83
educational level, and
(0.43- 1.61) duration of use
0.49
(0. 24-0.99)
0.44
(0. 18- 1.1 0)

Hospital based

Colorectal cancer
97 cases
3 3 8 controls (incidence)

Aspirin
< 1 day/week
0.52
over 4 years (0.3 0-0.91)
> 3 days/week
0.08
over 4 years (0. 01-0. 59)

Muscat et al. Hospital based
( 1994)

Colorectal cancer
51 1 cases
500 controls (incidence)

NSAIDs
2 3 days/week
for 2 1 year

N

RR = relative risk (incidence rate among exposed/incidence rate among unexposed)

Comments

Use during 4 years
before study

0.64
Men
(0.42-0.97)
0.3 2
Women
(0.18-0.57)

Table 2. 5 .
Authors

Summary of prospective studies and clinical trials ofNSAIDs use and colorectal cancer

Setting

Paganini-Hill Cohort:
et al. ( 1 989) LA retirement
community
1 98 1 - 1 988
Thun et al.
( 1 99 1 )
w

End Point

Colon cancer
1 3,897
1 8 1 cases (incidence)

Colon cancer
662,424
Cohort:
950 cases
(fatal)
American Cancer
Society
1 3 8 cases Rectum cancer
1 982- 1 988
(fatal)

U.S. polyp
Greenberg
et al. ( 1 993) prevention trial
Gann et al.
( 1 993)

Study Size

793 patients Recurrent
colorectal
with
adenomas
adenomas

U.S. Physicians' s 22,07 1 men
3 3 cases
Health Study
1 982- 1 988

Colorectal cancer
Colorectal polyps

NSAID
Dose
Aspirin
daily

Results
Comments
Relative Risk
1.5
( 1 . 1 -2.2)

Elderly ( median age 7 1)
Aspirin use determined
only on initial interview;
No ASA data after
baseline

Aspirin
For men
Aspirin use determined
< 1 use/month
only on initial in
0 . 77
(0.6 1 -0. 97) Results for women
were similar.
1 - 1 5 use/month
0 . 69
(0. 52-0. 93) Decreased risk mostly
� 1 6 use/month
0.60
confined to users of �
(0.40-0.89) 1 0 yrs
Aspirin
0 . 52
Colonoscopy minimized
any use at start (0. 3 0-0. 89) detection bias
and end of 1 year
Aspirin
325 mg every
other day

1.15
(0. 80- 1 . 65)
0 . 86
(0.68- 1 . 1 0)

The only available
randomized trial but
short follow up. This
study was terminated
after 4 years

Table 2 . 5 .
Authors

Setting

Study Size

Giovannucci
et al. ( 1 994)

Male health
professionals
(nonphysicians)
1 986- 1 990

4 1 ,000
50 cases

Nurses Health
Study
1 980- 1 992

47,900
50 1 cases

Giovannucci
et al. ( 1 995)
�
�

(Continued)

2 1 cases

End Point

NSAID
Dose

Results
Comments
Relative Risk

0.38
Colorectal cancer Aspirin
(incidence)
2: 2 times/week ( 0 . 1 8-0. 78)
0.08
Colorectal cancer
(metastatic disease
2: 2 times/week (0. 0 1 -0. 59)
or death)

Adjusted for age,
history of polyps, diet,
smoking, alcohol, and
physical activity

Colorectal cancer
(incidence)

Adjusted for age,
history of polyps, diet,
smoking, alcohol, and
physical activity

O. 62
Aspirin
2: 2 times/week (0.44-0. 86)
Duration of use
1 -4 years
1 . 06
(0. 78- 1 .45)
0. 84
5-9 years
(0. 55- 1 .28)
0.70
1 0- 1 9 years
(0.4 1 - 1 .20)
2: 20 years
0.56
(0.36-0.90)

RR = relative risk (incidence rate among exposed/incidence rate among unexposed)

Prevention of colon cancer in animal models with NSAIDs

Beginning in 1980, numerous studies in rodents (15 , 171, 207, 227-249) reported
that treatment with several NSAIDs (indomethacin, sulindac, piroxicam, aspirin and
others) effectively reduced tumor incidence and the growth of colonic polyps and cancer
in response to a variety of chemical carcinogens (Table 2.6). lndomethacin has been the
most actively investigated agent. In most cases, concomitant administration of the
carcinogen and indomethacin resulted in a reduced number of animals with tumors, and a
decreased number of tumors per animal compared with controls. Pollard and Luckert
(228) showed that indomethacin caused a 40% reduction in 1,2-dimethylhydrazine
induced intestinal tumors in rats. Narisawa et al. (207) demonstrated that rats exposed to
methylnitrosourea developed colonic tumors that could be significantly lowered by
indomethacin. However, in rats given the carcinogen and then indomethacin, a rapid
development of tumors occurred after IO-week cessation of treatment. Thus, the data
suggested that indomethacin inhibited the development of colonic tumors but did not
reject or kill the growing tumors. The influence of indomethacin and meclofenamate on
the development of dimethylhydrazine-induced tumors in rats was examined by Metzger et
al. (235). Colon cancer incidence was 56% in the indomethacin-treated animals, 90% in

the meclofenamate-treated group and 88% in untreated control group. Piroxicam was
shown to inhibit azoxymethane-induced colon cancer in rats in a dose-dependent manner
(239). At a dose of 150 ppm piroxicam, the incidence of colon tumor was reduced by as
much as 84% compared to untreated controls. In three studies (238, 243, 244), the
combined therapy with D,L-a-difluoromethylornithine, an ornithine decarboxylase
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Table 2.6.

0\

Effect ofNSAIDs in animal models for colorectal cancer
Carcinogen

Results

Rat
Rat

MAM

Dec. incidence and multiplicity
Dec. incidence, multiplicity and size

Indomethacin
Indomethacin

Rat
Rat

MNU

Inhibition of development
Dec. multiplicity

1982 lndomethacin
198 3 lndomethacin
198 3 Indomethacin

Rat
Rat
Rat

MNU
MNU

Inc. tumor number after drug stopped
Inhibits promotion and initiation
Dec. tumor incidence

1983 Piroxicam
198 3 Indomethacin

Rat
Mouse

MAM

1984 Indomethacin/
Meclofenamate
1984 Indomethacin
1984 Indomethacin

Rat

DMH

Rat
Rat

AMMN

MNU

1984 Piroxicam

Rat

MNU

Dec. incidence and multiplicity
Inhibits adenomas growth in transplantable
model
Dec. incidence with indomethacin
No protective effect with meclofenamate
Dec. multiplicity
PGE2 failed to overcome protective effect of
indomethacin
Dec.incidence and multiplicity

Rat
Rat
Mouse
Rat

AOM
AOM

Authors

Year NSAID

Kudo et al.
Pollard &
Luckert
Narisawa et al.
Pollard &
Luckert
Narisawa et al.
Narisawa et al.
Pollard &
Luckert
Pollard et al.
Sato et al.

1 980 Indomethacin
1980 lndomethacin
198 1
198 1

Metzger et al.
Narisawa et al.
Narisawa et al.
Pollard &
Luckert
Nigro et al.
Reddy et al.
Moorghen et al.
Ross et al.

1986
1987
1988
1988

Piroxicam
Piroxicam
Sulindac
Piroxicam

Animal

DMH

DMH

DMH

-------

DMH

-------

Dec. multiplicity, DFMO additive
Dose inhibitory response
Dec. incidence and multiplicity
Dec. tumor volume in transplantable model

Table 2.6.
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(Continued)

Authors

Year NSAID

Pollard &
Luckert
Moorghen et al.
Reddy et al.

1 989 Piroxicam

Animal

Carcinogen

Results

Rat

MAM

Dec. incidence and multiplicity

1 990 Sulindac
1 990 Piroxicam/

Mouse
Rat

DMH
AOM

Rao et al.

1 99 1

Rat

AOM

Dec. microadenomas
Both agents additive dee. in cancer incidence,
Single agents not effective versus adenomas
Dec. incidence and multiplicity

Skinner et al.

1 99 1

Rat

DMH

Craven &
DeRubertis

1 992 Aspirin

Rat

DMH

Reddy et al.
Davis et al.
Alberts et al.

Rat
1 993 Aspirin
Rat
1 994 Aspirin
Rat
1 995 Piroxicam
Sulindac
Sulindac sulfide

AOM
DMH
AOM

DFMO

Piroxicam/
DFMO
Sulindac

Dec. incidence and multiplicity;
reversed with PGE 1
Dec. incidence with aspirin given 1 week
before and after carcinogen;
No effect on incidence when started aspirin 4
weeks after carcinogen
Dec. incidence and multiplicity
Dose inhibitory response
All agents inhibit tumor number

AMMN, acetoxymethyl-methylnitrosamine; AOM, azoxymethane; DMH, dimethylhydrazine; MAM, methylazoxymethanol;
MNU, methylnitrosourea; DFMO, D,L-a-difluoromethylornithine; Dec., decreased; Inc., increased.

inhibitor, and piroxicam showed an additive inhibitory effect on tumor formation.
Sulindac was shown to have a protective effect against dimethylhydrazine-induced colonic
tumors in the mouse. Sulindac administered with the carcinogen resulted in a significant
reduction in tumor incidence and tumor burden, but sulindac administered 17 weeks after
the carcinogen administration had no inhibitory effect ( 15). Craven and DeRubertis (246)
examined the influence of aspirin on dimethylhydrazine-induced colonic carcinogenesis in
rats. Incidence of adenocarcinomas was reduced 69% in rats receiving aspirin for 1 week
before and after the carcinogen. However, aspirin had no effect on tumor incidence when
started 4 weeks after carcinogen exposure, though the dosage suppressed ex vivo colonic
PGE2 production by 95%.
In summary, a variety of reports generated in chemical carcinogen tumor model
support the concept that NSAIDs are effective in chemoprotection against rodent
colorectal cancer. These agents appear to work at the initiation and promotion stages of
carcinogenesis with different strengths of e:tfect.
NSAIDs and familial adenomatous polyposis (FAP)

In 198 3, Waddell and Loughry first reported that sulindac caused regression of
rectal adenomatous polyps in 4 patients with familial adenomatous polyposis ( 13). FAP is
an autosomal dominant inherited form of colorectal cancer in which patients develop
hundreds to thousands of adenomas throughout the colorectum. Inevitably, colorectal
cancer occurs, usually by the fifth decade of life. Waddell used sulindac (75-150 mg orally
twice a day) in FAP patients and noted a striking 70-100% polyp regression in these
persons. Following this initial account, similar observations of adenoma resolution with
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oral sulindac in FAP patients have been reported by several investigators (Table 2. 7) ( 12,
14, 206, 250-263). Polyp regression occurred in patients having various polyps and in
those with intact colons and in persons with ileorectal anastomosis. In 1991, a
randomized, placebo-controlled, double-blinded, crossover study in 9 FAP patients with
ileorectal anastomosis was conducted by Labayle et al. (252). Patients received sulindac
300 mg/day, or placebo during two 4 months periods separated by a 1 month washout
phase. With sulindac, a complete or almost complete regression of polyps was noted in all
patients. With placebo, polyp numbers increased in 5 patients, remained unchanged in 2
patients and decreased in 2 patients. Differences in polyp numbers between sulindac and
placebo groups were statistically significant. Nugent et al. reported a randomized
controlled trial of sulindac in 24 FAP patients with subtotal colectomy and ileorectal
anastomosis (255). Sulindac produced a statistically significant reduction in rectal polyp
count; however, the reduction in duodenal polyp count was not statistically significant. In
1993, Giardiello et al. reported the results of a study of 22 patients with FAP including 18
patients without prior colectomy (253). Patients received oral sulindac 300 mg/day or
placebo tablets for 9 months. A statistically significant decrease in mean polyp number
and size occurred in patients treated with sulindac compared with placebo at 3, 6 and 9
months. When the patients were reexamined 3 months after cessation of the treatment, an
increase in both the number and size of polyps was observed in sulindac-treated patients,
although they did not return to the pretreatment baseline. A similar result was published
by the same group in 1996 in which they further evaluate several clinical factors as
possible predictors of sulindac effect on regression of colorectal adenomas on patients
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Table 2.7.

Vl

0

Effect ofNSAIDs in human FAP patients

Authors

Year NSAID
(Dose: mg/day)

Waddell &
Loughry
Gonzaga et al.

1 983

Waddell et al.

1 989

Friend

1 990

Labayle et al.

1 99 1

Rigau et al.

1 99 1

Giardiello et al.

1 993

Hixson et al.

1 993

Nugent et al.
Tonelli &
Valanzano

1 985

Sulindac
( 1 50-300)
Sulindac
(Unspecified)
Sulindac
(300-400)
Sulindac
( 1 50)
Sulindac
(300)
Sulindac
(400)
Sulindac
(300)

Sulindac/
piroxicam
(400)/(20)
1 993 Sulindac
(400)
1 993 Sulindac
(200)

Study design

Results

Case series

Regression of adenomas in 4 F AP patients

Case series

Regression of adenomas in 2 F AP patients

Case series

Regression of adenomas in 7 F AP patients

Case report

Regression of polyps in 3 Gardner's patients

Randomizedcrossover
Case series

Regression of adenomas in 9 FAP patients

Randomized

Regression of adenomas size and number
Both the number and size increased after sulindac was
stopped (22 patients)
Regression of adenomas in 3/5 patients on sulindac
and 1 /2 adenomas patients on Piroxicam

Case series
Randomized
Case series

Regression of adenomas in 4 FAP patients

Regression of rectal but not duodenal adenomas
in 24patients
Regression of adenomas in 8/1 3 FAP patients

Table 2.7.

V'l

�

(Continued)

Authors

Year NSAID
(Dose: mg/day)

Winde et al.

1 993

Muller et al.

1 994

Niv & Fraser

1 994

Thorson et al.

1 994

Spagnesi et al.

1 994

Debinski et al.

1 995

Giardiello et al.

1 996

Hirota et al.

1 996

Sulindac
Suppository
(300)
Sulindac
(300)
Sulindac
(450)
Sulindac
(Unspecified)
Sulindac
(Unspecified)
Sulindac
(400)
Sulindac
(300)
Indomethacin
Suppository
(50- 1 00)

Study design

Results

Case series

Regression of adenomas with rectal administration

Case series
Case report

Regression of adenomas in 1 0 F AP patients, 1
juvenile polyp patients, 1 HNPCC patient
Rectal cancer in FAP patient while on sulindac

Case report

Rectal cancer in FAP patient while on sulindac

Case series

Regression of adenomas in F AP patients

Randomized

Sulindac only caused regression of duodenal polyp
with 2 mm or less in size
Regression of adenomas both in number and size in
FAP patients
Number of polyps decreased in 6/8 F AP patients;
however, the number increased after indomethacin
was discontinued

Randomized
Case report

FAP: familial adenomatous polyposis; HNPCC: hereditary nonpolyposis colorectal cancer

with FAP (263). They concluded sulindac treatment seems effective in producing
regression of colorectal adenomas of FAP patients with previous subtotal colectomy
regardless of baseline polyp number and size. Winde et al. and Hirota et al. ( 14, 256)
applied rectal administration of sulindac or indomethacin to achieve polyp disappearance.
Both of them suggested the rectal application may be useful in the future for adenoma
regression because this procedure is uncomplicated, morbidity rates are low, and
functional outcome is very good, even in the elderly. The effect ofNSAIDs on sporadic
colorectal adenoma regression ( adenomas in patients without a hereditary form of
colorectal cancer) has been evaluated in one small pilot study lasting 6 months. Hixson
and co-workers used piroxicam (20 mg/day) in 2 individuals with adenomas up to 10 mm
in size; only one polyp regressed partially (254). Of concern are several case reports of
FAP patients maintained on sulindac who subsequently developed rectal cancer (259,
260).
In summary, studies evaluating FAP patients have clearly shown that NSAIDs
cause the regression of adenomas polyps. This effect is fairly dramatic and occurs within
months after therapy has been initiated. In addition to orally administered sulindac, rectal
preparations also appear to be efficacious. The genetic defect and background in FAP
patients clearly differs from patients with sporadic adenomas , and these genetic
differences may have an impact on the effectiveness ofNSAIDs in causing regression of
adenomas which has not been well documented in patients with sporadic adenomas.
Studies of colon cancer in Min/+ mouse models with NSAIDs

Recently, a spontaneous intestinal tumor mouse model has been developed in
52

which C57BL/6J- Minl+ mouse, a strain containing a fully penetrant dominant mutation in
the Ape tumor suppressor gene, is used to study FAP and NSAIDs treatment in
experiments not possible with human patients (264-268). The mouse model allowed the
investigators to precisely control environmental and genetic conditions in the development
of neoplasia. All studies demonstrated that NSAIDs (piroxicam and sulindac)
significantly reduced the tumor multiplicity ofMini+ mice (Table 2. 8). In the sulindac
study, three groups of mice were compared: normal C57BL/6J (+/+) mice with the wild
type Ape gene, the dominant mutant C57BL/6J- Mini+ mice, and the Mini+ mice treated
with sulindac (at a dose of approximately 160 ppm in the drinking water beginning at 5-6
weeks of age) (265). Treatment with sulindac for approximate 9 weeks reduced average
tumor number to 0. 1 relative to the average of 11.9 tumors seen in untreated Mini+ mice.
Since sulindac treatment was started at 5-6 weeks of age, the results presented in this
study suggests sulindac affects tumor regression, rather than tumor initiation. To explain
these results, these authors examined the intestinal expression of cyclooxygenase-2 (COX2), as well as the levels of enterocyte apoptosis, in untreated mice (Mini+ and +/+) versus
sulindac-treated Mini+ mice. Untreated Mini+ mice had increased expression of COX-2
protein, increased levels of PGE2 in the intestine, and a 27-47% decrease in enterocyte
apoptosis compared to +/+ animals. Sulindac treatment of Mini+ mice decreased COX-2
expression and PGE2 production and restored apoptosis to levels similar to those observed
in +/+ mice. In a study using piroxicam, the Mini+ mice were given the drug continually,
via the diet, beginning at 30 days of age, and the tumor multiplicity was then assessed 6
weeks later (264). The results showed a dose-dependent decrease in intestinal adenomas
53

Table 2.8.

Effect ofNSAIDs in Mini+ mouse models

Authors

Mini+ mice

NSAID

Results

Beazer-Barclay
et al. ( 1996)

Male
Female

Sulindac
mixed with water
2 1 mg/I; 84 mg/I
mixed with diet
167, 3 34 ppm

Sulindac (84 mg/I with water
or 167 and 3 34 ppm with
diet) significantly decreased
tumor load

Boolbol et al.
( 1996)

Female

Sulindac
mixed with water
0.5 ± 0. 1 mg/day

Sulindac inhibited tumor
formation and restored PG:Ei
and apoptosis levels to
baseline

Jacoby et al.
(1996)

Female

Tumor multiplicity was
Piroxicam
decreased in a dose
mixed with diet
0, 50, 100, 200 ppm dependent response
TXB2 decreased in plasma
with piroxicam treatment

Barnes & Lee
( 1998)

Male
Female

Aspirin
mixed with diet
250, 500 ppm

Aspirin decreased tumor
multiplicity in small intestine
but not the colon and reduced
PGE2 synthesis in control
mice, whereas PGE2 synthesis
only was reduced significantly
with 500 ppm but not 250
ppm aspirin in the Mini+
rmce

Sulindac sulfide
Sulindac sulfone
mixed with water
0.5 ± 0. 1 mg/day

Sulfide significantly decreased
tumor number and PGE2 level
in tissue
Sulfone had a trend toward a
decrease in tumor number but
had no effect on PGE2 level

Mahmoud et al. Female
( 1998)

PGE2 : prostaglandin E2 ; TXB 2 : thromboxane B2
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and aberrant crypt foci as well as a parallel decrease in plasma level of thromboxane B2
(TXB2) . The fact that tumor multiplicity was reduced even though treatment was not
begun until 3 0 days of age suggest that piroxicam affects tumor promotion and /or
maintenance rather than tumor initiation. In another study, tumor number was reduced by
40-70% in Mini+ mice given sulindac in either the drinking water or the diet beginning at
approximate 30 days of age (266). Interestingly, a slightly stronger effect was observed
when treatment was begun prenatally by treating pregnant females. This suggests that
NSAIDs may be able to inhibit tumor formation and/or induce tumor regression.
Alternatively, tumor growth may be more effectively inhibited by early administration of
this drug. Mahmoud et al. reported the result of a study comparing the anti-tumor effect
of sulindac sulfide, the active anti-inflammatory metabolite of sulindac, and sulindac
sulfone, which has no anti-inflammatory activity ( 267). Mini+ mice were treated with
either sulfide or sulfone (0.5 mg/day) in drinking water. Mini+ mice and homozygous
C57BL/6J-+/+ normal litter-mates lacking the Ape mutation were used as controls. At
110 days of age, control Mini+ mice developed 3 3 .2 ± 6.6 tumors per mouse compared to
0.6 ± 0.3 tumors for sulindac sulfide-treated Mini+ mice and 2 1.9 ± 4.5 tumors per
mouse for sulfone-treated Mini+ mice. Decreased enterocyte apoptosis was observed in
Mini+ control mice and Mini+ mice treated with sulfone. Sulfide restored apoptosis to

normal level in the mucosa ofMini+ animals and decreased PGE2 level in the small
intestine of treated Mini+ animals by 59%. With respect to the efficacy of aspirin, wild
type and Mini+ mouse were fed a diet supplementated with aspirin (250 or 500 ppm) or
without aspirin for 7 weeks (268). Aspirin significantly reduced tumor multiplicity in the
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small intestine, but not the colon, from an average of 3 5. 8 tumors per mouse to 16 and
18.5 tumors per mouse with 250 and 500 ppm aspirin treatment, respectively. PGE2
synthesis only was reduced significantly with 500 ppm aspirin in the Mini+ mice. In
summary, the results of these studies lend further evidence that NSA.IDs can have valuable
chemopreventive and / or chemotherapeutic potential to protect from colorectal cancer.

POSSIBLE MECHANISMS OF NSAIDs IN CANCER PREVENTION

The precise mechanisms explaining the chemopreventive and/or chemotherapeutic
efficacy ofNSAIDs against colorectal neoplasia are still unclear. Several hypotheses have
been proposed.
Hypothesis I: Cyclooxygenase as the target of NSAIDs

The commonly proposed hypothesis of the antitumor effect of NSAIDs is to inhibit
cyclooxygenase activity and subsequently reduce the prostaglandin biosynthesis.
Numerous studies have shown that prostaglandins are actively involved in cell growth and
neoplastic cellular transformation. Many transformed cells produce more prostaglandins
than normal cells and this excess amount of prostaglandins in tum can facilitate the growth
of tumor cells. Enhanced prostaglandin production by naturally occurring or
experimentally induced cancers has been documented in many studies ( 16 1, 269)
(265). The mRNA of COX-2 was markedly elevated in colorectal adenocarcinomas and a
subgroup of colonic adenomas as compared with levels in adjacent normal tissues,
suggesting an increase in the expression of COX-2 may be involved in the progression of
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tumor development (208). Enhanced COX-2 expression was also observed in patients
clinically diagnosed with colorectal cancer (208-210). Prostaglandin synthesis inhibitors
such as aspirin, indomethacin and sulindac have been demonstrated to inhibit cancer
growth in laboratory animals, in vitro and in clinical studies (220, 247, 248, 270). Taken
together, the role of COX-2 leading to increased PGE2 production in colon cancers
implies that the antitumor effect ofNSAIDs on colon carcinogenesis may be mediated by
inhibition of COX-2.
Hypothesis II: Inhibition of cell growth by NSAIDs

One proposed mechanism by which NSAIDs may affect tumorigenesis is their
influence on the arachidonic acid cascade, whose products have been implicated in the
initiation, promotion, growth and spread of tumors, as well as in the immune response to
cancers. NSA IDs have been noted to affect cell proliferation in variety of experimental
models, thus giving insights into their antitumor activity. For example, several NSA IDs
have been shown to directly inhibit growth of rat hepatoma and human fibroblast cells in
culture, and to suppress transplantable murine colon adenocarcinoma (234, 27 1).
Indomethacin was also shown to arrest theG1-S progression in the cycle of cultured cells
and reduce overall DNA synthesis (272, 273). The mechanism of this effect may be the
inhibition of other cell cycle-related enzymes, for example, cA MP kinase and
phosphodiesterases (274).
Hypothesis ill: Enhancement of immunosurveillance by NSAIDs

NSAIDs have been shown to diminish growth of malignant cells by a direct effect
on cells that enhances immune surveillance in the cancerous tissue. NSAIDs decrease
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PGE2 production and can stimulate cellular immune function both in vitro and in vivo
(275). Treatments with NSAIDs has been shown to enhance a variety of immunological
responses which may restore antitumor immunity in a compromised host. Prostaglandins
play a role in host antitumor immunity by modulating a variety of immunological
responses. For example, high levels of tissue PGE2 are frequently associated with
suppression of immune surveillance and killing of malignant cells. PG£i can act as a
feedback inhibitor for cellular immune processes, such as T-cell proliferation, lymphokine
production and cytotoxicity (276). In general, either increased production or increased
sensitivity to normal amounts of PGE2 results in depressed cellular immunity. Conversely,
immune responses are generally enhanced by NSAIDs that inhibit prostaglandin synthesis,
thus partially explaining the antitumor activity.
Hypothesis IV: NSAID-induced apoptosis

The proposal that NSAIDs may promote cell death is based on studies showing
that prostaglandins are mitogenic, and that high concentrations of prostaglandins exist in
certain tumors and tumor cell lines ( 16 1, 269). One hypothesis is that the anti-neoplastic
activity ofNSAIDs is mediated by their inhibition of prostaglandin synthesis. PGEi can
induce apoptosis of both immature normal and malignant B-lymphocytes (277). This may
suggest that PGE2 secreting cells such as macrophage, which inhibit the B-cell
microenvironments of lymphoid organs, may eliminate a subset of immature B
lymphocytes, and this may be important in controlling the spread of malignant lineages.
There is the histologic evidence that treatment with mefenamic acid and diclofenac can

58

induce apoptosis in the crypts of colorectal biopsy tissue from patients who developed
gastrointestinal irritation in response to NSAIDs (278, 279). Several animals and cell lines
studies also demonstrated that sulindac can induce apoptosis in Mini+ mice and human
colon HT-29 adenocarcinoma cell lines (265, 280, 28 1). Therefore, apoptosis has been
suggested to be one consequence ofNSAIDs' anti-neoplastic activity.

RESEARCH OBJECTIVE

The commonly accepted hypothesis of the antitumor effect ofNSAIDs is directly
related to their ability to reduce eicosanoid biosynthesis by inhibiting cyclooxygenase
activity. The overall objective of this dissertation is to assess the relationship of
eicosanoids, particular prostaglandin E2, to intestinal tumor load in the Mini+ mouse
model.
To accomplish this objective, the following specific aims will be investigated:
Specific Aim 1:

To characterize the tumor development (number and size) and
eicosanoid (PGE2 , 6-keto PGF 1a, and LTB4) levels in the normal
appearing intestinal tissue and tumors and to examine the potential
effect of nonsteroidal anti-inflammatory drug (NSAID) sulindac on
intestinal tumor load and tissue eicosanoid levels in the Mini+
mouse model.

Specific Aim 2:

To investigate the temporal effect ofNSAID sulindac on tumor
load and the effects of sulindac on established tumors in the Mini+
mouse model.
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Specific Aim 3:

To evaluate the impact of enhancing eicosanoid biosynthesis using
dietary arachidonic acid (AA) on tumor load with and without
sulindac supplementation in the Mini+ mouse model.

Specific Aim 4:

To study the effect of other NSAIDs, indomethacin and aspirin, on
tumor load and correlate these effects to eicosanoid production
generated from normal appearing intestinal tissue and tumors in the
Mini+ mouse model.
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PART ID

SULINDAC CAUSES RAPID REGRESSION OF PREEXISTING TUMORS IN
MINI+ MICE INDEPENDENT OF PROSTAGLANDIN BIOSYNTHESIS

This chapter has been published in similar format with co-authors McEntee, M.F.,
Whelan, J. in: Cancer Research 57, 4267-4273, 1997
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ABSTRACT
Several lines of evidence strongly link prostaglandins (PGs) and leukotrienes (L Ts)
to cancer of the intestine. Several studies have reported a 40-50% reduction in mortality
from colorectal cancer in individuals who routinely consume nonsteroidal anti
inflammatory drugs, possibly by inhibiting cyclooxygenase activity. However, the role of
eicosanoids in this process is still unclear. The heterozygote Mini+ mouse model, like
patients with familial adenomatous polyposis, carries a nonsense mutation in the
adenomatous polyposis coli ( APC) gene that results in the spontaneous development of
intestinal adenomas (100% incidence). This study investigated the association between
eicosanoid biosynthesis, intestinal tumor load and the chemotherapeutic effect of the
nonsteroidal anti-inflammatory drug sulindac during early and preexisting phases of tumor
growth and development as well as residual effects after drug withdrawal. Administration
of sulindac ( 320ppm) to Mini+ mice reduced the tumor number by 95%, but did not alter
the levels of PGE2 and LTB4 in intestinal tissues. Increasing PGE2 and LTB4 levels by
44% with dietary arachidonic acid supplementation had no effect on tumor number or size.
When sulindac was added to the arachidonic acid-supplemented diet, tumor number was
reduced by 82%, whereas eicosanoid levels remained elevated. In Mini+ mice with
established tumors, treatment with sulindac for 4 days reduced tumor number by 75% and
continual administration of sulindac was necessary to maintain a reduced tumor load. In
summary, alterations in eicosanoid formation were not correlated with tumor number or
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size in the Mini+ mouse model; thus, the antitumor effect of sulindac seems to be PG
independent.

INTRODUCTION
Heterozygous C57BL/6J-Min (Mini+) mice are highly susceptible to spontaneous
development of intestinal adenomas due to a germline mutation in one allele of the murine
adenomatous polyposis coli (APC) gene with tumor initiation following loss of
heterozygosity (1-3). The importance of this tumor suppressor gene to the phenotype has
been recently confirmed by targeted mutagenesis (4, 5). The Mini+ mouse is a model for
human intestinal tumorigenesis with similarities to an inherited form of human intestinal
cancer, familial adenomatous polyposis (FAP). Individuals with FAP carry a mutation in
one allele of the APC gene resulting in multiple intestinal adenomas following somatic
mutation or loss of the second allele (2).
Several lines of evidence demonstrate an inverse relationship between the use of
nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and sulindac, and
intestinal cancer. NSAIDs have been shown to reduce the relative risk of intestinal cancer
in humans by 40-50% (6-14). Sulindac, in particular, decreases intestinal tumor load in
Mini+ mice and FAP patients ( 12, 13) and inhibits chemically-induced colonic tumors in

mice ( 15). Sulindac is a pro-drug and lacks anti-inflammatory activity until it is modified
in the liver and by colonic bacteria to its metabolically active sulfide derivative ( 16). Since
one of the major pharmacologic effects ofNSAIDs is to inhibit cyclooxygenase (COX)
activity, decreased prostaglandin (PG) biosynthesis is reasonably assumed to be an
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important mechanism of action for these drugs. Boolbol et al. ( 1 7) have reported that the
small intestine of Mini+ mice has elevated expression ofCOX-2 and increased production
of PGE2 compared to that of age-matched wild type controls. When treated with sulindac,
they found that a reduction in tumor load was associated with a reduction in PGE2
formation and COX-2 expression compared to untreated Mini+ mice. However, it has yet
to be clearly established that the antitumor effect of sulindac is mediated via a reduction in
prostaglandin biosynthesis. A number of studies suggest a prostaglandin-independent
mechanism ( 1 8-2 1 ). For example, both sulindac metabolites (sulfide and sulfone
derivatives) have similar anti-neoplastic effects; however, only the sulfide derivative
inhibits cyclooxygenase ( 1 9).
Sulindac use is associated with regression of preexisting adenomas in FAP patients
and its use is required for maintenance of a reduced tumor load in these individuals (22).
Sulindac treatment in weanling Mini+ mice results in dramatic reductions in tumor
frequency. It appears that intestinal tumors in Mini+ mice are initiated early in life and
that sulindac may be causing tumor regression in this model, perhaps by increasing
apoptosis ( 1 7, 1 9, 23-24). However, studies to date have yet to establish that sulindac can
cause regression of preexisting tumors in Minl+ mice. In a chemically-induced colonic
tumor model, sulindac has a protective effect when provided concurrently with the
carcinogen 1 ,2-dimethylhydrazine, but does not cause tumor regression (25). In the
present study, we present data that shows that: (a) the antitumor effect of sulindac rapidly
eliminates (within 4 days of treatment) macroscopic evidence of established tumors in
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Mini+ mice; (b) this effect may be independent of prostaglandin modulation; and (c)
withdrawal of the drug is associated with reappearance of tumors.

MATERIALS AND METHODS
Animals
Wild type ( +/+) and Mini+ (Apel+) male C57BL/6J mice (Jackson Laboratories,
Bar Harbor, l\1E), 3 5-40 days of age, were randomly divided into treatment groups ( 4-8
animals per group). They were housed in suspended stainless steel cages in a temperature
controlled room (23±2°C) with a 12-h light-dark cycle and given free access to food and
water. The health of the animals were checked daily. Prior to sacrifice, all animals were
fasted over night. All animal procedures were approved by the University of Tennessee
Animal Care and Use Committee and were in accord with the NIH Guide for the Care
and Use ofLaboratory Animals (National Research Council, 1985).
Diets
The control (drug-free) diets were composed of purified AIN-93G powder diet
(Dyets, Inc., Bethlehem, PA). Sulindac (Sigma Chemical Co., St. Louis, MO) was
administered to the diets by thoroughly mixing 320 ppm sulindac with control diet. For
those experiments using diets with modified fatty acid compositions, diets were
supplemented with 1.5% (w/w) of the following fatty acid ethyl esters, oleic acid or
arachidonic acid (Nu Chek Prep, Elysian, MN). All diets were prepared weekly and
stored at -20°C. All animals were provided fresh food daily to prevent oxidation. Food
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consumption was monitored daily and animal weights were recorded weekly and the
actual drug doses were calculated according to food intakes.
Experimental Design

Experiment 1: Sixteen wild type (WT) male mice and sixteen male Mini+ mice

were each divided into four groups of four animals upon arrival (approximately 3 5 days of
age). One group each of wild type and Mini+ mice were sacrificed at 77, I O I and 1 1 5
days of age. The fourth group of wild type and Mini+ mice were treated with sulindac (S)
(supplemented in the diet) at 320 ppm from the time of arrival through 1 15 days of age, at
which time they were also sacrificed. Body weight and food consumption for all animals
were monitored. At the time of sacrifice, tumor number, size and location were
determined. Portions of normal appearing intestine and several of the largest tumors were
harvested for histologic examination. The production of PGE2, 6-keto-PGF1a and LTB4
from samples of normal appearing small intestine (mid-jejunum) were determined for each
animal. Small intestinal tumors were also harvested from untreated I O I and 1 1 5 day old
animals for PGE2, 6-keto-PGFia and LTB4 analysis.
Experiment 2: Twenty-six male Mini+ mice (35-40 days of age) were randomly

divided into four groups upon arrival with (+S) or without (-S) sulindac supplementation.
All animals were initially provided a sulindac-free diet until approximately 77 days of age
(an average of 37 days). The animals in groups +S2 (n=7) and +S4 (n=8) were then
provided sulindac (320 ppm) in the diet for 2 or 4 days prior to sacrifice, respectively.
The animals in the +S20 group (n=S) were sacrificed following 20 days of sulindac
supplementation. Tumor number, size and location were determined and samples were
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harvested for histologic examination. A control group ofMini+ mice not treated with
sulindac was sacrificed at approximately 80 days of age (-S; n=6 ).
Experiment 3: Twelve male Mini+ mice approximately 40 days of age were
randomly divided into two groups upon arrival. One group (n=6) was provided a diet
containing sulindac ( 320 ppm) from the time of arrival until 80 days of age, at which time
they were switched to a sulindac-free diet for 40 days. At 120 days of age, the animals
were sacrificed and tumor number, size and location were determined.The second group
ofMini+ mice (n=6) was also provided a diet containing sulindac from the time of their
arrival ( approximately 40 days of age) until 80 days of age and sacrificed at day 80 to
provide tumor load data following 40 days of sulindac treatment.
Experiment 4: Twenty male Mini+ mice approximately 35-40 days of age were
randomly divided into four groups (5 animals/group) whose diets were supplemented
( 1.5% w/w) with the ethyl ester of oleic acid ( 18: l n-9, OA) or arachidonic acid (20:4n-6,
AA), with or without sulindac (320 ppm). All mice were provided diet ad libitum until 60
days of age, at which time they were sacrificed and tumor number, size and location, tissue
fatty acid composition, and eicosanoid production were determined.
Gross and Histologic Examination

At the scheduled age, the entire intestinal tract from each animal was removed and
flushed with cold (4°C) phosphate buffered saline (PBS). Each intestinal tract was opened
longitudinally and spread out, mucosa! surface up, so that the location (large or small
intes-tine), size and number of tumors could be determined using a dissecting microscope
( 18x). Tissue samples were fixed in 10% neutral buffered formalin (NBF). Five µm
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paraffin embedded sections were stained with hematoxylin and eosin (H&E) for
histological evaluation.
Eicosanoids Measurement

After sacrifice, normal-appearing intestinal sections (mid-jejunum) and pooled
samples of individually excised small intestinal tumors were homogenized using a Polytron
homogenizer in O.IM cold Tris-HCI buffer (pH 7. 4). Ex vivo production of eicosanoids
was determined by incubating the homogenate for 15 min. The reaction was terminated
by methanolic acidification following the addition of 8. 8% of cold formic acid in methanol
(final pH 3.5). Eicosanoids were isolated by solid phase extraction using an octadecyl
(C 18) cartridge (Burdick & Jackson, Muskegon, Ivfl) and eluted with 100% methanol. The
recovery of eicosanoids was determined by adding 10 nCi [3H]-PGD2 to the sample as an
internal standard prior to processing. Recoveries averaged 80% and were not statistically
different among groups. The methanol was evaporated under an atmosphere of nitrogen
and the extracts were resuspended in phosphate buffered saline (PBS), pH 7.4, containing
0. 1% gelatin. PGE2, 6-keto-PGF 1« and LTB4 were measured by radioimmunoassay as
described previously (26) using antiserum obtained from PerSeptive Diagnostics, Inc.
(Cambridge, MA). All standards were purchased from Cayman Chemical (Ann Arbor,
Ivfl) and [3H]-PGE2, [3H]-PGD2, [3H]-6keto-PGF 1a and [3H]-LTB4 were obtained from
New England Nuclear (Boston, MA). An aliquot of the homogenate from each sample
was used to determine protein concentration (27).
Fatty Acid Analysis

The fatty acid methyl esters of the tissue phospholipids were prepared and
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analyzed as previously described (26). Briefly, tissues were homogenized in cold saline
and lipids were extracted with chloroform/methanol ( 1: 2 v/v), followed by extraction (x2)
with chloroform. The pooled chloroform extracts were evaporated and resuspended in a
small volume of chloroform and the phospholipids were separated by thin layer
chromatography on silica gel 60 HP-TLC plates (Merck, Darmatadt, Germany) with
chloroform/methanol (8: 1 v/v) as the solvent system. Bands corresponding to the
phospholipids were scraped, dissolved in toluene and saponified with 0.5 mM KOH in
methanol for 8 min. at 86°C. Following acidification with 0.7 mM HCl in methanol, the
fatty acids were extracted with hexane ( x2 ), evaporated and methylated with ethereal
diazomethane. The fatty acid methyl esters were resuspended in hexane and analyzed
using a Hewlett-Packard model 5890 series II gas chromatograph equipped with flame
ionization detector and a DB2 3 fused silica capillary column (0.25 mm I.D. x 30 m x 0. 25
µ film) (J&W Scientific, Folsom, CA). Separation was achieved by temperature
programming from 160 to 250°C at 3.5°C/min with hydrogen as the carrier gas. The
internal standard, pentadecanoic acid ( 15: 0) methyl ester (100 µg) was added to each
sample prior to the saponification process. The fatty acid methyl esters were identified by
comparison of retention times with those of known standards.
Statistical Analysis

The Statistical Analysis System (SAS Institute, Inc, Cary, NC) was employed to
analyze the data. Data were expressed as means ± SEM. Differences in body weight,
food consumption, tumor number and biochemical parameters between the groups were
analyzed statistically by a Students t-test or analysis of variance (ANOVA). Fisher's Least
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Significant difference multiple comparison method was used to determine differences
among groups. Data was considered significant at p � 0.05.

RESULTS
Food Intake and Body Weights

The general condition and health ofMini+ mice were not affected by sulindac
treatment or dietary fatty acid manipulation. The Mini+ mice were approximately 10%
smaller (by weight) than age-matched controls upon arrival (data not shown). Body
weights of the wild type mice (WT), WT plus sulindac (WT+S) and Mini+ plus sulindac
(Min+S) mice increased at similar rates throughout the study, but the rate of body weight
gain in untreated Mini+ mice (Min) plateaued at approximately 77 days of age. The WT
mice consumed significantly more food than the Mini+ mice independent of sulindac
treatment ( 3. 2±0.lg/d versus 2.8±0.lg/d). Although both Mini+ groups (Min and
Min+S) consumed similar amounts of food, the rate of body weight gain by the sulindac
treated group paralleled that of the wild-type mice, while the untreated animals failed to
gain weight after 77 days of age. We attribute this lack of weight gain in the untreated
group to a greater tumor load in these animals as discussed below.
Food intake and body weight gain were not different between the oleic acid and
arachidonic acid supplemented groups (data not shown).
Effect of Age and Sulindac Treatment on Tumor Frequency, Size and Morphology

No tumors were found in the WT mice. At 77 days of age, Mini+ mice maintained
on the control diet had approximately 40±5 tumors per animal with a mean tumor size of
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1.2 mm (Table 3. 1). The total tumor number remained relatively constant between 77
days and 115 days of age. Compared to the 77 day old mice, the average tumor size
increased 43% and 52% at ages 101 days and 115 days, respectively. Overall, more than
95% of the tumors were located in the small intestines. There was no significant
histologic distinction between the largest tumors harvested from 77, 101 or 115 day old
Min/+ mice. In addition to features previously described (28), tumors frequently
contained intraepithelial granulated leukocytes and scattered apoptotic bodies. Granulated
cells had large brightly eosinophilic cytoplasmic granules and a round to indented
hyperchromatic nucleus. These cells were not found in the normal intestinal mucosa
outside of the tumors. There was frequently loss of at least a portion of the surface
epithelium in larger tumors with exposure of the supporting stroma/lamina propria to the
intestinal lumen. This tumor ulceration was far less common in the smaller lesions.
Melena, frank intestinal hemorrhage, and splenomegally with marked erythropoiesis was
most prominent in older animals carrying the heaviest tumor loads. This intestinal
hemorrhage clearly results in a significant compensatory demand on body resources, as
evidenced by the marked splenic erythropoiesis, and likely accounts in large part for the
failure to gain weight as noted previously. When sulindac was supplemented to the diet
for 80 days, tumor number and size were 93% and 55% lower, respectively, when
compared to the unsupplemented 115 day old Min/+ mice (Table 3. 1) and there was little
to no evidence of melena or erythropoietic splenomegaly. Tumors from untreated and
treated animals were histologically indistinguishable.
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Table 3. 1.

Effect of age and sulindac on tumor size and number in the colon and small
intestine of Min/+ mice
Age of Mini+ mice (dayst
77
(n= 4)

101
(n= 4)

115
(n= 4)

l l 5+Sulindac
(n= 4)

Total tumor number/group
Colon
< 1 mm
1-1. 5
2-2. 5
3-3. 5
4-4. 5
5-5.5
Small Intestine
< 1 mm
1-1. 5
2-2.5
3-3. 5
4-4. 5
Total #/group
Ave.Tumor #!moused
Ave. Tumor Siz�

2b
2

4
6
1
2

1

1

1
1

2
9
86
65
6

61
74
14
5
158
39. 5±4.6e
1. 20±0. 0 l h

18 1

e

45 .3±6.o

1 . 7 1±0 . 03 e

4
82
63
9
3

8
3

164
4 l . 0±4.6e

12
3. 0±1. 11
0. 8 3±0. 071

l . 82±0 . 02e

Mini+ mice were fed AIN-93G powder diet from arrival and sacrificed at 77, 101, and
115 days of age. One group was supplementated with 320 ppm sulindac from arrival
through 115 days of age. Tumor number and size were examined from the entire intestinal
tract using a dissecting microscope ( 18x).
b Number of tumors.
cNone observed.
dMean±SEM (n= 4 animals/group).
e Values in each row with different superscript letters are significantly different by
ANOVA ( p < 0. 05).
1 Significantly different from age-matched ( 115 day old) non-sulindac treated Mini+ mice
by Student's t test ( p < 0.0001).
g Average size (mm) was calculated as a weighted average for each size classification and
expressed as Mean±SEM.
h Values in each row with different superscript letters are significantly different by
ANOVA ( p < 0.05).
a

98

Temporal Effects of Sulindac on Established Tumors
In order to determine if sulindac would cause regression of pre-existing tumors
and, if so, how soon sulindac's effect would be observed, animals were provided a
sulindac-free diet for an average of 37 days following arrival and then supplemented with
sulindac for either 2, 4 or 20 days. When sulindac was administered for two days, the
number of tumors identifiable under a dissecting microscope was 19% lower than in the
age-matched Minl+control group which received no sulindac (29±3 vs 36±7 tumors)
(Table 3. 2). Within four days of sulindac treatment, tumor number (9±1) was 75% lower
than the untreated group, with only a slight further reduction (7±2 tumors) after 20 days
of sulindac treatment.
Under the dissecting microscope, small intestinal tumors from animals treated for 2
and 4 days were generally flatter than those in untreated animals and some had a slightly
translucent, granular appearance. There were also scattered approximately 1-2 mm
diameter crateriform lesions ( an average of I0/mouse) in the small intestine. These
depressions in the mucosa! surface were lined by villi which were shrunken or absent
centrally and had a white-frosted appearance around the perimeter of the lesion. Colonic
tumors were not significantly different from those in untreated mice. After 20 days of
sulindac treatment, tumors identified under the dissecting microscope were not
significantly different from those of untreated mice.
Histologically, the tumors from animals treated for 2 days were flatter with a slight
increase in villus architectural distinction, a reduction in the density of tubular-glandular
structures, a relative increase in the amount of loose connective tissue between the glands,
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Table 3. 2.

Temporal effects of sulindac on established tumors in the colon and small
intestine of Min/+ mice
Treatment groupa
-S
(n=6)

+S2
(n= 7)

+S4
(n=8)

+S20
(n=5)

Total tumor number/group
Colon
< 1 mm
1-1. 5
2-2.5
3-3.5
4-4.5
5-5. 5
Small Intestine
< 1 mm
1-1.5
2-2. 5
3-3.5
4-4. 5
Total #/group
Ave. Tumor/moused
Ave.Tumor Siz�
a

b

1c

4
3

4
3
1

I
2
1

2

58
132
20
1

74
119
4

34
35

15
17

2 18
36. 3±7.3e
1. 14±0. 0l e

206
29. 4±2.7e

0. 99±0. 0 lf

73
9. 1±0. W

o. 92±0.0Y

34
6.8±1.&

0. 89±0. 0it

Mini+ mice were provided a sulindac-free diet for an average of 37 days following

arrival. Groups of +S2, +S4, and +S20 were then provided with 320 ppm sulindac in the
diet for 2, 4 or 20 days prior to sacrifice, respectively. Tumor number and size were
examined from the entire intestinal tract using a dissecting microscope ( 18x).
b None observed.
cNumber of tumors.
dMean±SEM.
e Values in each row with different superscript letters are significantly different by
ANOVA ( p < 0. 05).
1 Values in each row with different superscript letters are significantly different by
ANOVA ( p < 0. 05).
g Average size (mm) was calculated as a weighted average for each size classification and
expressed as Mean±SEM.
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and a more vertical orientation of the remaining glands. There was no evidence of
significant increases in apoptosis or decreases in mitosis in H&E stained sections but there
were occasional cystic glands filled with necrotic cellular debris. The crateriform lesions
had no evidence of residual tumor cells and consisted of centrally shrunken, misshappen
villi or ulceration surrounded by villi lined by epithelial cells with variably abundant
cytoplasmic lipid droplets. Some of the tumors from animals treated for 4 days had similar
changes to those seen after 2 days treatment with even more restoration of villus and crypt
architecture. These lesions also contained intraepithelial granulated cells in some cases,
similar to the untreated tumors. Other tumors in this 4 day treatment group showed less
evidence of architectural normality or reduced tubular-glandular structures. Small cystic
structures ( single crypts) lined by proliferating epithelial cells were found incidentally in
samples of small intestine from 2 and 4 day treated animals, resembling those occasionally
seen in untreated Min/+ mice. Colonic tumors of treated animals were not significantly
different from those of untreated animals.
Residual Effect of Sulindac Treatment on Tumor Number and Size

In order to determine if continued use of sulindac was required for maintenance of
a reduced tumor load, animals were treated with sulindac for 40 days then placed on a
sulindac-free diet for an additional 40 days. Following 40 days of sulindac
supplementation (40-80 days of age), tumor number and size averaged 2.0±0. 8 per mouse
and 0.92±0. 08 mm in diameter, respectively (Table 3. 3). After a further 40 days on
sulindac-free diet (80-120 days of age), the number of tumors increased to 28.8±6. 0 per
mouse with an average diameter of 1. 14±0. 03 mm.
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Table 3. 3.

Residual effect of sulindac treatment on tumor Size and number in the
colon and small intestine of Min/+ mice
Treatment groupa
+S
(n=6)

+S :-S(40)
(n=6)

Total tumor number/group
Colon
< 1 mm
1-1. 5
2-2. 5
3-3. 5
4-4.5
5-5. 5
Small Intestine
< 1 mm
1-1.5
2-2.5
3-3.5
4-4.5
Total #/group
Ave. Tumor/moused
Ave. Tumor Size&'
a

b

1
1
1
1
5
3

31

1 17

20
1

12
2. 0±0.s e
0.92±0. 0Se

173
28. 8±6.<Y
1. 14±0. 0Y

Mini+ mice were treated with 320 ppm sulindac in the diet for 40 days; one group (+S)

was sacrificed to provide tumor load data after 40 days of sulindac treatment. The other
group (+S:-S(40)) was then placed on a sulindac-free diet for an additional 40 days.
Tumor number and size were examined from the entire intestinal tract using a dissecting
microscope (18x).
b None observed.
c Number of tumors.
d
Mean±SEM (n=6 animals/group).
e Values in each row with different superscript letters are significantly different by
Student's t test ( p < 0. 05).
f Values in each row with different superscript letters are significantly different by
Student's t test ( p < 0. 05).
g Average size (mm) was calculated as a weighted average for each size classification and
expressed as Mean±SEM.
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Prostaglandin and Leukotriene Production by Normal Appearing Small Intestine
and Tumors
The production of PGE2, 6-keto-PGF 1« and LTB 4 was not different in normal
appearing intestines of wild type animals and the Mini+ mice at 77, 101 or 115 days of
age and was not reduced following sulindac treatment (Figs. 3.1-3.3). The small intestinal
tumors of the Mini+ mice produced significantly higher levels of PGE2 and LTB 4 in the
IO 1 and 115 day old mice compared to normal appearing small intestinal tissues (Figs. 3 .1
and 3.2). 6-keto-PGF 1« production was not significantly different between the tumors and
normal appearing intestines at 101 days of age, but was significantly lower at 115 days of
age (Fig. 3 .3).
Effect of Dietary Arachidonic Acid on Intestinal Fatty Acid Composition,
Eicosanoid Production, Tumor Frequency and Size
Arachidonic acid was provided in the diet to enrich tissue phospholipids with
arachidonic acid and augment eicosanoid biosynthesis and to evaluate what impact these
changes would have on tumor frequency and/or size.
Intestinal Fatty Acid Composition: Tissue arachidonic acid levels in the
arachidonic acid-supplemented groups were 60% higher compared to the oleic acid
supplemented groups, independent of sulindac treatment (Table 3 .4). The increase in
arachidonic acid levels occurred along with a concomitant decrease in linoleic acid levels,
an effect typically observed with arachidonic acid feeding (26).
Prostaglandin and Leukotriene Production: Human and animal studies have
clearly demonstrated that supplementing diets with arachidonic acid augments eicosanoid
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PGE2 production was not different in normal appearing intestinal sections from wild type (WT), Mini+ (Min), wild
type plus sulindac (WT+S), Mini+ plus sulindac (Min+S) mice fed AIN-93G powder diet and sacrificed at 77,
1 0 1 , and 1 1 5 days of age. However, small intestinal tumors from Mini+ (Min-Tumor) mice produced elevated
amounts of PGE2 . Columns represent the means of four experimental values; bars, SEM. * significantly different
from all other groups, p < 0.05.
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6-keto-PGF 1 a production was not different in normal appearing intestinal sections from wild type (WT), Mini+
(Min), wild type plus sulindac (WT+S), Mini+ plus sulindac (Min+S) mice fed AIN-930 powder diet and
sacrificed at 77, 1 0 1 , and 1 1 5 days of age. Small intestinal tumors from Mini+ (Min-Tumor) mice did not
produce significantly different amounts of 6-keto-PGF Ia at 1 0 I days of age but the amount was significantly lower
at 1 1 5 days of age compared to normal appearing intestines. Columns represent the means of four experimental
values; bars, SEM. * significantly different from other groups, p < 0.05.

Table 3 .4.

Small intestine phospholipid fatty acid composition of Min/+ mice whose
diets were supplemented with dietary arachidonic acid or oleic acid and
with or without sulindac
Treatment group a

Selected
fatty acidsb

OA
(n =5)

OA+S
(n=5)

AA
(n =5)

A A +S
(n = S )

18:2 (n-6)

23 . 1 1±1 .09c

20.73±0.93 c

15.2 I±0.79d

I 6.03±0.49d

20:4 (n-6)

15.7 I±0.29d

I5.73±0.32 d 24.62±0. 7gc

25 . 66±0.36c

a Mini+ 35-40 day old mice were fed AIN-93G powder diet supplemented with 1.5%
(w/w) ethyl esters of oleic acid or arachidonic acid with 320 ppm sulindac (OA +S ; A A+S)
or without sulindac (OA ; AA ) until 60 days of age. Phospholipids were separated by TLC
and methylated using ethereal diazomethane and the fatty acid methyl esters were then
analyzed via gas chromatography.
b Data are mol% and summarized as Mean±S EM (n = S animals/group).
c Values in each row with different superscript letters are significantly different by
ANOVA ( p < 0.05).
avalues in each row with different superscript letters are significantly different by
ANOVA ( p < 0.05).
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biosynthesis systemically, and as such, provides an effective non-invasive technique to
elevate prostaglandins and leukotrienes in vivo (26, 29-3 1). The feeding of arachidonic
acid resulted in a significant increase (approximately 42% overall) in the production of
PGE2, 6-keto-PGFia and LTB4 . Treatment with sulindac had no effect on reducing
eicosanoid production, in particular, the prostaglandins PGE2 and 6-keto-PGFl a (Fig.
3. 4).
Tumor Frequency and Size: Arachidonic acid supplementation had no effect on
tumor number compared to oleic acid, but the average size of the tumors were 15%
smaller (Table 3.5). Sulindac treatment reduced the number of tumors by 96% and 8 3%
in the oleic acid and arachidonic acid groups, respectively. The average size of the tumors
in the sulindac-treated animals were not different among the arachidonic acid and oleic
acid-supplemented groups.

DISCUSSION

The objectives of this study were to evaluate the progression of the Mini+
phenotype over time, evaluate the temporal effect of the NSAID sulindac as a
chemopreventive or therapeutic agent for intestinal tumors, and detennine whether
alterations of eicosanoid biosynthesis are related to sulindac's effect.
Mini+ mice averaged 42 intestinal tumors/mouse over the course of the study

(Table 1), which is consistent with other laboratories where genetically similar Mini+ mice
(i.e., on a C57BL/6J background) develop an average of 30-60 macroscopically visible
tumors by the age of 90 days ( 32-34). Our results suggest, under normal conditions
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Table 3.5.

Tumor size and number in the colon and small intestine of Min/+ mice
supplemented with arachidonic acid or oleic acid and with or without
sulindac treatment
Treatment groupa
OA
(n=5)

OA+S
(n= S)

AA
(n=S)

AA+S
(n=S)

Total tumor number/group
Colon
< 1 mm
1-1. 5
2-2.5
3-3.5
4-4.5
5-5.5
Small Intestine
< 1 mm
1-1.5
2-2.5
3-3.5
4-4.5
Total #/group
Ave. Tumor/moused
Ave. Tumor Size&'

b
gc

4

1

3

4

102
66

18
8

171
34. 2±6. 4e
0.8 2±0.011

29
5.8±0.4/
0.79±0.09

1

84
103
5

201
40. 2±3. l e
0.97±0.0l e

1

2

9

1. 8±0. &
0.9±0.l f
e

a Mini+ 35-40 day old mice were fed AIN-9 3G powder diet supplemented with 1.5%
(w/w) ethyl esters of oleic acid or arachidonic acid with 320 ppm sulindac (OA+S; AA+S)
or without sulindac treatment (OA; AA) until 60 days of age. Tumor number and size
were examined from the entire intestinal tract using a dissecting microscope (18x).
b None observed.
c Number of tumors.
d Mean±SEM (n=5 animals/group).
e Values in each row with different superscript letters are significantly different by
ANOVA ( p < 0.05).
IValues in each row with different superscript letters are significantly different by
ANOVA ( p < 0.05).
g Average size (mm) was calculated as a weighted average for each size classification and
was expressed as Mean±SEM.
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intestinal tumor initiation has occurred by 60 days of age based on two features: ( 1) the
average number of tumors per mouse did not increase between 60 and 115 days of age
(see Tables I and 5) and� (2) the relative number of tumors less than Imm in size are
reduced as the animals aged with an equivalent increase in those greater than Imm in
diameter. This shift in tumor size is consistent with growth of pre-existing tumors and
minimal induction of new tumors as the animal ages. Tumor initiation before 60 days of
age is in agreement with data generated by Shoemaker et al. ( 3 3).
Consistent with the results of other studies ( 17, 34), treatment ofMini+ mice with
sulindac shortly after genetic screening resulted in stark reductions in tumor frequency.
With withdrawal of sulindac treatment, tumor frequency increased indicating an obligate
requirement of sulindac treatment for this anti-tumor effect. We also demonstrated similar
results in Mini+ mice with pre-existing macroscopically evident tumors. We
demonstrated a maximum impact of sulindac' s effect on pre-existing tumors within four
days of treatment. Tumors, 2 and 4 days post-treatment, differed slightly, both
macroscopically and histologically, when compared to tumors of untreated animals. The
tumors from treated animals appeared flatter with some loss of tubular and glandular
structures and more obvious vertically oriented crypts suggesting reappearance of a more
normal small intestinal architecture. Apoptosis was not clearly increased in H&E stained
tumors from animals treated with sulindac for 2 days. This does not, however, rule out
the possibility of a role for apoptosis in regression of these lesions as it was apparent that
considerable changes had already taken place by the time these tissues were harvested. It
is entirely possible that elimination of apoptotic neoplastic cells had already occurred
11 1

through phagocytosis or desquamation into the intestinal lumen following 2 days of
treatment. In addition, evaluation ofH&E stained sections may not be the most sensitive
technique for detection of cells undergoing this process.
While the mechanisms by which sulindac causes regression of adenomas has yet to
be clarified, the drug has been shown to induce apoptosis, possibly by inhibiting COX-2
(17-18, 23). Over-expression of COX-2 has been observed in established Mini+ mouse
tumors ( 35) and has been linked to inhibition of apoptosis (17-18, 2 3, 35, 3 6). Therefore,
inhibition of prostaglandin biosynthesis is a convenient explanation for sulindac' s effects.
However, a growing body of contradictory evidence suggests the possibility of a
prostaglandin-independent mechanism.
Prostaglandin and leukotriene production was not different in normal appearing
intestinal tissue from Mini+ mice compared to their wild type litter mates at any age. We
did, however, find that tumors produced significantly higher levels of PGE2 and LTB4 at
IO I and 115 days of age and significantly lower levels of 6-keto-PGF 1a at 1 15 days of age
compared to normal appearing intestine, but it is still not clear as to whether these are
important in tumor growth. There appears to be an antithetic relationship between the
levels of PGEi and PGI2 (measured as 6-keto-PGF 1a) in tumor cell lines and neoplastic
colonic tumors in humans ( 37, 38). Increasing eicosanoid biosynthesis as a result of
dietary manipulation with arachidonic acid had no effect on tumor frequency and did not
result in larger tumors. However, it is possible that basal eicosanoid production exceeds
the minimum threshold for effectiq.g tumor wtiationlpromotion and any effects on tumor
load are observed oniy..after inhibiting eicosanoid biosynthesis. In addition, our eicosanoid
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data does not fully address the involvement of COX-2. Tumors over-express COX-2 in
humans and Mini+ mice compared to adjacent normal-appearing tissue and this may
account, in part, for the increased production of PGE2 ( 35, 39, 40). Histologic
examination demonstrated that tumors were infiltrated by intra-epithelial granulated
leukocytes which may be a source of the elevated levels of PGE2 and LTB4 observed in
this study. While it has been reported that normal appearing intestinal tissue from Mini+
mice produces significantly higher levels of PGE2 and over-express COX-2 compared to
wild type litter mates ( 17), others have more recently reported that COX-2 is not
expressed in normal appearing intestine in both Mini+ and the APC-716 mouse model (a
transgenic strain of Min mice) ( 35, 36). These recent data are more consistent with our
results and, as such, eicosanoid levels in normal small intestines ofMini+ and wild type
mice can not be used to distinguish the Mini+ phenotype.
In addition to the sulfide metabolite of sulindac which has anti-COX activity, the
drug is also oxidized in vivo to its sulfone derivative (4 1). Sulindac sulfone has been
shown to be a relatively ineffective inhibitor of either COX-1 or -2 ( 16), but has
antiproliferative effects and induces apoptosis in various tumor cell lines ( 19, 2 1).
Recently, the sulfone derivative was also shown to be effective in inhibiting chemically
induced colonic and mammary carcinogenesis (20, 28) and colonic preneoplastic lesions
(42) without inhibiting prostaglandin biosynthesis, raising the question as to whether
sulindac is acting via inhibition of prostaglandins. It is currently unclear whether sulindac
sulfone is contributing to the antitumor effect of sulindac in Mini+ mice.
In summary, sulindac acts very quickly (within 4 days) to cause regression of small
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intestinal tumors in Mini+ mice, while long term effectiveness requires constant use of the
drug. Although the mechanism by which sulindac decreases tumor load is unclear, its
ability to inhibit COX-2 activity and/or decrease COX-2 expression is believed to be
related to induction of apoptosis which likely has a role in the regression process. Our
data suggests that tumor load is not correlated with eicosanoid production and that the
ability of sulindac to reduce tumor load in the Min/+ mouse model does not appear to be
dependent upon the inhibition of prostaglandins, in particular, PGE2 .
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ABSTRACT
Epidemiologic and animal studies indicate that sustained use of NSAIDs have a
chemopreventive effect against the incidence of colorectal neoplasia and subsequent
mortality. We previously demonstrated that sulindac significantly reduces intestinal tumor
load in Mini+ mice apparently independent of prostaglandin biosynthesis. In the present
study, we show that indomethacin (9 ppm) is a very potent chemopreventive agent
reducing tumor load by 85% and significantly inhibiting basal and ex vivo prostaglandin
formation (p < 0. 006 and p < 0. 0001, respectively). Aspirin (400 ppm) has a similar
impact on prostaglandin levels, but in contrast to indomethacin, is uneffective in reducing
the tumor load. The data indicate a discordance between the impact of different NSAIDs
and their anti-neoplastic activity.

INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) reduce chemically-induced and
genetically predetermined colorectal tumors in experimental animal models and the risk of
developing colorectal cancer in humans (1-8). Aspirin is the most widely used NSAID
and has a unique mechanism of action in inhibiting cyclooxygenase activity (9). Whereas
most epidemiological studies report a 40-50% reduction in the incidence of colorectal
cancer with regular aspirin use, some studies report that the incidence of colorectal cancer
actually increases slightly in aspirin users ( 10, 11). However, prospective clinical trials
designed to specifically investigate the effectiveness of aspirin as a therapeutic agent on
intestinal tumors have not been done in spite of the epidemiologic evidence supporting its
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efficacy ( 12). In clinical trials, the NSAID sulindac is very effective in reducing tumor
number and size in famalial adenomatous polyposis (FAP) patients, individuals who carry
a germline mutation in the tumor suppressor gene adenomatous polyposis coli (APC) ( 13,
14). Similarly, sulindac reduces intestinal tumor load by 90-95% and the number of pre
existing tumors by 80% in Mini+ mice, an animal model for FAP that also carries a
germline mutation in murine APC (6). While NSAIDs like sulindac and piroxicam (5) are
very effective in reducing tumor number in Mini+ mice, there is recent evidence
suggesting aspirin may not be as effective as other NSAIDs in this model ( 15). This study
was designed to evaluate the efficacy of aspirin and indomethacin as chemopreventive
agents on intestinal tumors in Mini+ mice.

MATERIALS AND METHODS
Animals
Male C57BL/6J Mini+ (Apel+) mice were obtained at 35 days of age (Jackson
Laboratories, Bar Harbor, ME) and were randomly assigned into treatment groups (4-5
animals per group) at the time of arrival. Mice had free access to food and water at all
times and their health was checked daily. All animal procedures were approved by the
University of Tennessee Animal Care and Use Committee and were in accord with the
NIH Guide for the Care and Use ofLaboratory Animals (NRC 1985).
Diet
The control (drug-free) diets were composed of purified AIN-93G powder diet
(Dyets, Inc., Bethlehem, PA). Experimental diets were prepared weekly by thoroughly
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mixing 400 ppm aspirin or 9 ppm indomethacin (Sigma Chemical Co., St. Louis, MO)
with the control diet. Diets were stored at -20°C and all animals were provided fresh food
daily. Food consumption was monitored daily and animal weights were recorded weekly.
Drug doses were calculated based on actual food consumed.
Experimental Design:

Experiment 1: Twelve male C57BL/6J Mini+ (Apel+) mice were assigned to three groups

(drug-free, aspirin (ASA) or indomethacin), four animals per group. All mice were
maintained on respective diets to 80 days of age, at which point, tumor number, size and
location were determined as previously described (6). The production of PGE2 and 6keto-PGFIa from samples of normal appearing small intestine were determined for each
animal.
Experiment 2: Ten male C57BL/6J Mini+ (Apel+) mice were randomly assigned to two

groups (drug-free or aspirin), five animals per group and treated as described above to
confirm the aspirin results from experiment 1.
Eicosanoids Measurement

Intestinal mucosa was homogenized using a Polytron homogenizer in O.l M cold
Tris-Rel buffer (pH 7. 4). An aliquot of the homogenate from each sample was used to
determine protein concentration with a modified Lowry assay. The production of
eicosanoids was determined in intestinal mucosa homogenates by incubating them at 3 7°C
for O (basal level) and 15 min (ex vivo production). The incubation was stopped by adding
indomethacin (final cone. lmM), followed by adding 8. 8% of cold formic acid in methanol
(final pH 3. 5). Eicosanoids were isolated by solid phase extraction using an octadecyl
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(C 18) cartridge (Burdick & Jackson) and eluted with 100% methanol. The recovery of
eicosanoids was determined by adding 10 nCi [3H]-PGD2 to the sample as an internal
standard prior to processing. The methanol was evaporated under an atmosphere of
nitrogen and the extracts were resuspended in phosphate buffered saline (PBS), pH 7 .4,
containing 0.1% gelatin . PGE2 and 6-keto-PGF 1« were measured by radioimmunoassay as
described previously (6) and according to the manufacture's instruction with antiserum
obtained from PerSeptive Diagnostics, Inc. (Cambridge, MA). All standards were
purchased from Cayman Chemical (Ann Arbor, :MI) and [3H]-PGE2, [ 3H]-PGD2 and [3H]6-keto-PGF 1« were obtained from New England Nuclear (Boston, MA).
Statistical Analysis

The Statistical Analysis System (SA S Institute, Inc, Cary, NC) was employed to
analyze the data . Data were expressed as means ± S EM . Differences in tumor load
(number and size) and biochemical parameters between the groups were analyzed
statistically by analysis of variance (ANOVA ). The Fisher least significant difference at p
� 0.05 was tested to compare means.

RESULTS
Dietary Intake and Body Weights

Growth rates corresponded to food intake. Food intake and growth rates among
the Mini+ mice groups were similar, independent of drug treatment (data not shown).
There was no evidence of toxicity due to aspirin or indomethacin treatment in any of the
nuce.
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Effect of Aspirin and lndomethacin on Tumor Number and Size
The untreated Mini+ mice developed an average of 29±5.6 tumors by 80 days of
age, whereas those supplemented with aspirin or indomethacin developed 50±13.6 and
4. 5±0.7 tumors/mouse, respectively (one animal on aspirin treatment developed 89
intestinal tumors) (Table 1). Tumor number was not significantly different among the
control and aspirin-treated groups. The average size of the tumors was unaffected by any
treatment (Table 1). A second experiment confirmed that aspirin treatment had no effect
on reducing the tumor number and size compared to untreated Mini+ mice (i. e. 32.6±9.5
vs. 32. 0±5. 7) (Table 2).
Prostaglandin Formation
Basal and ex vivo eicosanoid production were evaluated in normal appearing
intestines from drug-free Mini+ mice and Mini+ mice treated with aspirin or
indomethacin.
Basal levels of PGE2 and 6-keto-PGF 1 a were significantly lower in the animals
treated with indomethacin compared to untreated controls (Table 1). Ex vivo PGE2 and
6-keto-PGFIa production was also significantly lower in both the aspirin and indomethacin
treated groups compared to untreated controls (Table I). In the second aspirin study,
basal levels and ex vivo production of PGE2 and 6-keto-PGF1a were again significantly
lower in the aspirin-treated mice compared to untreated Mini+ mice (Table 2).

DISCUSSION
NSAIDs have been shown to be effective chemopreventive agents for a number of
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Table 4. 1.

Tumor load and eicosanoid production from normal appearing intestine in
Mini+ mice treated with aspirin or indomethacin
Treatment group 1
Aspirin
(n= 4)

Untreated
(n= 4)

Indomethacin
(n= 4)

29. 3±S.6a
1. 18±0. 0S a

4.5±0.7b
1. 16±0.l l a

50±13.6a
l . 10±0. 03a

Eicosanoids4
Basal level (ng/mg total protein)
PGE2
0.74±0. 12a
6-keto-PGF1 a
0.64±0.11a

0. 46±0.04b
0.18±0. 02b

ND5
ND

ex vivo production (ng/mg total protein)
PGE2
6.94±1.65a
6-keto-PGF1 a
4.65±0.92a

l.87±0.66b
0.16±0. 26b

l. l l±0.07b
1. 39±0.IOb

Tumors
Avg. Tumor #lmouse2
Avg. Tumor Size3

1

Mini+ mice were fed purified AIN-93G powder diet from arrival through 80 days of
age. NSAIDs were administered by thoroughly mixing 400 ppm aspirin or 9 ppm
indomethacin with control diet. Tumor number and size were examined from the entire
intestinal tract using a dissecting microscope ( l 8x).
2
Mean±SEM.
3
Average size (mm) was calculated as a weighted average for each size classification and
expressed as mean±SEM.
4
ng/mg total protein
5
Not determined ( see experiment 2)
a, b V
alues in each row with different superscript letters are significantly different by
ANOVA, at p < 0.05.
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Table 4.2.

Tumor load and eicosanoid production from normal appearing intestine in Mini+
mice treated with or without aspirin
Treatment group1
Untreated
(n=5)

Aspirin
(n=5)

Tumors
Avg.Tumor #lmouse2
Avg. Tumor Size3

32.6±9. S a
l.04±0. 09a

32. 0±5.7a
l.10±0.04a

Eicosanoids4
Basal level (ng/mg total protein)
PGE2
6-keto-PGFia

l .62±0.27a
0.62±0.12a

0. 40±0. 0Sb
O.I5±0. 02b

ex vivo production (ng/mg total protein)
PGE2
6-keto-PGF1 a

6.9I±0. 36a
3.57±0. 27a

2. 02±0.I6b
l. 07±0. 08b

1

Mini+ mice were fed purified AIN-93G powder diet from arrival through 80 days of age.
Aspirin was administered by thoroughly mixing 400 ppm aspirin with control diet. Tumor number
and size were examined from the entire intestinal tract using a dissecting microscope (18x).
2
Mean±SEM.
3
Average size (mm) was calculated as a weighted average for each size classification and
expressed as mean±SEM.
4
nglmg total protein
a,b Values in each row with different superscript letters are significantly different by ANOVA, at
p < 0. 05.
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cancers, including colorectal cancer, and it has been presumed that this is due to their
ability to inhibit prostaglandin formation (2, 9, 16). A spirin use, in particular, reduces the
relative risk of intestinal cancer in humans by 40-50% (7, 8) and inhibits intestinal
tumorigenesis in chemically-induced rodent models (2) ; however, several recent studies
indicate that aspirin use may not be associated with a reduction in incidence or risk of
colorectal cancer (10, 11). Similarly, aspirin was an ineffective chemopreventive agent in
a chemically-induced mouse model of urinary bladder cancer, while other NSA.1Ds, such
as ketaprofen and sulindac, significantly decreased the incidence of transitional cell
carcinoma of the urinary bladder by > 70% in these animals (17).
The results presented in this paper demonstrate that while both aspirin and
indomethacin decreased eicosanoid biosynthesis in the intestine, only indomethacin
reduced the tumor load in these animals. We observed that tumor number and size were
not significantly different in two independent experiments with aspirin used at a dose of
1.2 mg/day for these male mice, but that basal and ex vivo production of PGE2 and 6-keto
PGF la were significantly reduced by 77-88%. A clear explanation for these seemingly
dichotomous results is complex if one assumes that NSA.1Ds reduce tumor load by
inhibiting prostaglandin biosynthesis. Other NSAIDs such as sulindac ( 4, 6) and
piroxicam (5) are as efficacious as indomethacin in reducing tumor load in the Mini+
mouse model, suggesting that aspirin may not be as effective in reducing tumor load as
other NSAIDs. Our results contrast a recent paper by Barnes and Lee who reported that
treatment ofMini+ mice with aspirin at a dose of 1.3 mg/day and 1 .2 mg/day for males
and females, respectively, resulted in a 55% reduction in tumor number, but had no effect
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on intestinal mucosa PGE2 production ( 1 5). The contrasting results observed in
prostaglandin production in these two studies may be explained by differences in
experimental and analytical methodologies. The diets were different, tissue preparations
for eicosanoid measurements were dramatically different, analytical procedures were
different and expression of the data was different.
Aspirin's inability to reduce tumor load is perplexing since the commonly accepted
hypothesis for the antitumor action of NSAIDs centers around their ability to reduce
prostaglandin biosynthesis. The efficacies of aspirin and indomethacin may be related to
their mode of action in inhibiting COX-2 (as reviewed in Ref. 9). Indomethacin is a slow
irreversible inhibitor of both COX-I and COX-2 by binding tightly to the active sites of
the enzymes. Acetylation of the active sites by aspirin irreversibly inhibits COX-1 activity
and modifies the product profile of COX-2, from PGG2 to15(R)-HETE. However, the
kinetic differences between indomethacin and aspirin for the inhibition of COX-2 activity
may provide insight as to their abilities to reduce tumor load. The relative potencies of
aspirin and indomethacin to inhibit COX-I and COX-2 using purified enzymes, broken cell
preparations and intact cells are similar, but the IC50 values for aspirin on COX-2 activity
are > 1 00 times higher than those ofindomethacin ( 18). However, differences in the ability
to inhibit COX-2 may only provide a partial explanation. Administration of the selective
COX-2 inhibitors nimesulide and :MF-tricyclic reduced intestinal tumor number by 50% in
Mini+ mice ( 1 9) and 60% in APC�716 knockout mice (20), respectively, significantly less
than the 85-95% reductions observed following treatment with indomethacin, piroxicam
or sulindac, which are preferential inhibitors of COX-I (5, 6). Even cross-breeding
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APC,:1716 knockout mice with COX-2 knockout mice failed to eliminate all intestinal tumors
(20), suggesting that COX-2 activity is an important, but partial determinant of intestinal
tumor load and that multiple mechanisms may contribute to the chemopreventive efficacy
ofNSAIDs . Taken together, these results suggest that aspirin may not be as effective in
reducing tumor load in the Mini+ mouse model when compared to other NSAIDs, such as
indomethacin, and that inhibition of prostaglandin production may not fully explain their
antitumor effects.
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SUMMARY AND CONCLUSION
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The commonly accepted hypothesis of the antitumor effect ofNSAIDs is directly
related to their ability to reduce eicosanoid biosynthesis by inhibiting cyclooxygenase
activity. To address this hypothesis we set out to establish a positive relationship between
eicosanoid biosynthesis, in particular prostaglandin E2, and intestinal tumor load in the
Mini+ mouse model. We used this model because most human intestinal cancers have an

underlying defect in the APC gene and Mini+ mice are genotypically and phenotypically
similar to human FAP (Table 2. 2). Mini+ mice were treated with different NSAIDs
sulindac, aspirin and indomethacin, each with a distinct ability to inhibit cyclooxygenase
activity, to curtail and dietary arachidonic acid to augment eicosanoid biosynthesis.
Our data demonstrated that sulindac and indomethacin are very potent
chemotherapeutic agents in which they significantly reduced the tumor load by ""95% and
""85%, respectively. However, aspirin, the most commonly used NSAID and a potent
cyclooxygenase inhibitor, had no effect on reducing tumor load. Both aspirin and
indomethacin significantly reduced basal and ex vivo levels of PGE2 and 6-keto-PGF 1a;
however, administration of sulindac failed to reduce eicosanoid production in intestinal
tissues. In addition, increasing overall eicosanoid biosynthesis with dietary arachidonic
acid supplementation had no effect on tumor number or size; suggesting the antitumor
effect ofNSAIDs appears to be independent of eicosanoid biosynthesis. These results are
not without precedence. For example, whereas most epidemiological studies report a 4050% reduction in the incidence of colorectal cancer with regular aspirin use, some studies,
nevertheless, report that the incidence of colorectal cancer actually increases slightly in
aspirin users (1, 2). Barnes and Lee reported that aspirin, at a dose which decreased
13 3

tumor load by 50% in the Mini+ mouse, did not inhibit prostaglandin production ( 3). In
addition, sulindac sulfone, a metabolite of sulindac which lacks the ability to inhibit
cyclooxygenase, reduced tumor load by 25% and 60% in Mini+ mice and the AOM
induced colonic tumor rat model. Despite the fact that our data and that of others
demonstrate an inconsistent relationship of eicosanoid biosynthesis and tumor load, there
is sufficient evidence linking the AA cascade with intestinal cancer. For example, Ohima
et al. ( 4) crossbred COX-2 knock out mice with ApcL,716 knock out mice and reduced
tumor load by 86%. This data clearly demonstrated that COX-2 is involved in
tumorigenesis but this study also clearly demonstrated that COX-2 is only partially
responsible because not all tumors were eliminated in the COX-2 knock out mice.
Overall, these data suggest that multiple regulatory mechanisms may contribute to the
chemopreventive efficacy ofNSAIDs.
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APPENDIX I
TISSUE FATTY ACID ANALYSIS
Note: KEEP EVERYTHING AS COLD AS POSSIBLE
Part I: Extraction of fatty acids
1).

Liver was perfused and small intestine was washed with cold saline and removed from
animal for immediate process or freezing in liquid nitrogen and store at -80°C

2).

Homogenize tissues in cold 0.9% saline (l OOmg/ml) with glass homogenizer.

3).

Transfer 0. 8ml of homogenates into teflon coated 16 x 125 screw top tubes and add
3ml of chloroform:methanol ( 1: 2).

4).

Vortex and incubate for 30 min. on ice in dark condition.

5).

Add 200 µl saturated NaCl and 1ml of chloroform to each sample.

6).

Vortex and incubate for 15 min. on ice in dark condition.

7).

Centrifuge at 900xg for 3 min. (Solely for phase separation)

8).

Remove chloroform layer.(bottom layer) and transfer to 12 x 75 mm test tube.

9).

Extract one more time by adding 1 ml chloroform and follow the steps 6-8.

10).

Evaporate the chloroform under nitrogen to dryness.

1 1).

Resuspend the fatty acid extraction in 50 µl chloroform.

12).

Separate polar fraction (phospholipids) and non-polar fraction (triglyceride,
cholesterol, and free fatty acids) with TLC (Thin Layer Chromatography) by mobile
phase: chloroform:methanol (8: 1).
Place filter paper in the TLC chamber and pour mobile solvent CHCl3 :MeOH (8: 1)
into chamber
For liver: apply 25 µl to TLC silica gel 60 HP-TLC plates
For small intestine: apply all 50 µI to TLC silica gel 60 HP-TLC plate
Add additional 200 µl chloroform to each tube and flush with nitrogen and store at
-20°C.
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13).

Place TLC plate into chamber and run TLC for about 15 min. or until solvent reach
the top line. Dry TLC plate under hood .

Part Il: Saponification, acidification, and methylation of fatty acids

14).

Phospholipid fraction is scraped from point of origin of plate using razor blade and
placed in a 16 x 125 mm screw top tube (make sure the tops fit tightly).

15).

A dd 100 µl 15:0 ( lmg/ml in iso-octane) to the screw top tubes as internal standard.

16).

A dd 0.25 ml toluene (for solubilization)

17).

Saponify the fatty acids with 0.5 ml 0.5 N KOH/MeOH, cap the tube tightly and
incubate at 86°C water bath for 8 min.

18).

Cool tubes to room temperature.

19).

A cidify with 1 ml of0.7N HCI/MeOH.

20).

Extract fatty acids with 2 ml ofHexane, vortex well, centrifuge at 900 x g for 3 min.
and transfer top layer to 12 x 75 mm tubes .

21).

Repeat steps 19-20 IX and evaporate to dryness under nitrogen gas.

22).

Resuspend lipids in 200 µl Hexane and transfer to V-vial and evaporate under
nitrogen. A dd additional 200 µl Hexane to tube and repeat transfer and evaporate
IX.

23).

Under the hood, add 150-200 µl ethereal diazomethane and incubate 10 min. (put the
caps loosely on immediately after ) for fatty acid methylation. (Bubble air will be
seen)

24).

Evaporate to dryness under the hood.

25).

Resuspend methylated lipids in hexane, cap and vortex .
For liver: Bring up to I 00 µl
For small intestine : Bring up to 10 µl

26).

A nalyze via gas chromatograph.
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APPENDIX II
TISSUE EICOSANOID ANALYSIS by RADIOIMMUNOASSAY (RIA)
Part I. Tissue (small intestine) Eicosanoid Extraction
A. Ex vivo eicosanoid extraction:
Weight tissue and record
1.
Homogenize tissue in 1200 µl of cold Tris-HCI (0.1 M, pH 7.4)
2.
Transfer 100 µl to a 12 x 75 mm tube for protein Lowry assay
3.
Transfer 1000 µl to a 12 x 75 mm cap-fit tube and incubate at 37°C water bath for 15
nun.
At the end of the incubation, add 250 µl of 3H-PGD2 (0. 4 µCi I IO ml PBSG = 10
4.
nCi I 250 µl PBSG) as internal standard
Take 4 µl of 3H-PGD2 and suspend in 10 ml PBSG will generate 0.4 µCi I IO
ml of stock 3H-PGD2
5.
6.
7.
8.
9.
1O.
11.
12.
1 3.
14.
15.

Stop the reaction with 100 µl cold acid methanol solution (90% of 100% MeOH +
10% of 88% formic acid, pH 3. 5, make it one day before using and store at 4°C)
Vortex well and place on ice
Prepare C1 8 Sep-Pak cartridge (rinse with the order of water, MeOH , water)
Pour samples through Sep-Pak
Using 10% MeOH-formic acid to rinse tube and pass through Sep-Pak
Completely dry cartridge
Collect elute with 2 ml 100% MeOH twice into a 12 x 75 tube
Evaporate MeOH under nitrogen
Add 250 µl PBSG, vortex well
Take 5 0 µl for internal standard recovery test by sintillation counting
Sample is ready for RIA assay

B. Basal eicosanoid extraction:
1.
2.
3.
4.
5.

Weight tissue and record
Homogenize tissue in 1120 µl of cold Tris-HCl (0.1 M, pH 7. 4) with 80 µl of
indomethacin (stock cone. 15 mM), a COX inhibitor (final cone. 1 mM)
Transfer 100 µl to a 12 x 75 mm tube for protein Lowry assay
Transfer 1000 µl to a 12 x 75 mm cap-fit tube
Add 250 µl of 3H-PGD2 (0.4 µCi / 10 ml = 10 nCi / 250 µl) as internal standard
Take 4 µl of 3 H-PGD2 and suspend in 10 ml PBSG will generate O.4 µCi I 10
ml of stock 3H-PGD2
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6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.

Stop the reaction with 100 µl cold acid methanol solution (90% of 100% MeOH +
10% of 88% formic acid, pH 3.5, make it one day before using and store at 4°C)
Vortex well and place on ice
Prepare C 18 Sep-Pak cartridge (rinse with the order of water, MeOH , water)
Pour samples through Sep-Pak
Using 10% MeOH-formic acid to rinse tube and pass through Sep-Pak
Completely dry cartridge
Collect elute with 2 ml 100% MeOH twice into a 12 x 75 tube
Evaporate MeOH under nitrogen
Add 250 µ1 PBSG, vortex well
Take 50 µI for internal standard recovery test by sintillation counting
Sample is ready for RIA assay

Part II. Radioimmunoassay (RIA)
A. Reagent Preparation

1)

PBSG buffer: (Keep at 4°C approximately one week)
O. lM pH 7. 4 phosphate buffered saline (0.9%) with gelatin (0. 1%)

(based on 500 ml formula)
2.7 grams NaH2P04.H20
8. 2 grams NaifIP04. 7H20

Sodium Phosphate Monobasic
Sodium Phosphate Dibasic (Disodium Hydrogen
Phosphate)

4.5 grams NaCl
0.5 grams gelatin
Predissolve gelatin in 100ml water and heat at 50-70 °C ( 122 -158 °F) prior
to addition to the buffer
Bring volume up to 450 total (pH ,..,, 6.825)
Adjust to pH 7.4 with NaOH
Q.S. to 500ml with distilled water
2) Antiserum (Ab): (Advance Magnetics)
Reconstitute the antiserum with amount of the PB SG buffer as
instructed on the label and store at -20 °C
* Antiserums are packed under vacuum, need precaution when reconstitute
- Inject 2 ml of PGSB into the antiserum bottle with Hamilton syringe to wet
the powder antiserum and avoid explosion of antiserum to the air
when the cap is opened
- Inject air into the bottle to decrease the vacuum
- When the vacuum is low, open the rubber cap carefully, and add the rest
volume of required PBSG into the bottle
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3) Tracer Preparation 3H-Antigens (*Ag) (New England Nuclear)
Stock solution for:
3

H-PGE2 contains 18,000 cpm/0.1 ml PBSG
H-6-keto-PGF 1a contains 12,000 cpm/0.l ml PBSG
3
H-LTB4 contains 18,000 cpm/0.1 ml PBSG
Store at -20 °C
3

4) Standard Eicosanoid Preparation (Ag)
1. Eicosanoid standards come with 1 mg powder
2. Dilute with 1 ml Iv1EOH; the concentration will be 1 mg/ml rvIBOH
3. Taking IO µl eicosanoid-Iv1EOH solution (1 mg/ml), evaporating rvIBOH, diluting
with 1 ml Iv1EOH again. The concentration will be 10 µglml = 10,000 ng/ml
rvIBOH (stock solution)
4.To prepare working solution, evaporate 10µ1 of stock solution (100 ng/10 µI) and
redissolve in 1ml PBSG buffer, the concentration will be (100 ng/ml PBSG)
Store at -20 C.
Dilute working solution (WS) with PBSG buffer as follows:
Stds
Tubes

Cone.
(pg/0.1 ml)

S-1
S-2
S-3
S-4
S-5
S-6
S-7

2000
667
222
74
24.7
8.2
2.7

Log
Cone.
0. 2 ml WS plus 0.8 ml PBSG
0.5 ml of S-1 plus 1. 0 ml PBSG
0.5 ml of S-2 plus 1. 0 ml PBSG
0.5 ml of S-3 plus 1. 0 ml PBSG
0.5 ml of S-4 plus 1.0 ml PBSG
0.5 ml of S-5 plus 1.0 ml PBSG
0.5 ml of S-6 plus 1. 0 ml PBSG

3. 30
2.82
2.35
1.87
1.39
0.91
0. 43

Use standard tubes (S-1 - S-7) to generate the-standard curve
Prepare standards shortly before use
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5) Dextran-Coated Charcoal (DCC)
2.5g Activated Charcoal
300mg Dextran
250 ml PBSG buffer
The charcoal suspension is heated at 50-60 °C ( 122-140 °F) for 30 min. with stirring,
then chilled in ice water and stored at 4 °C. (Prepare DCC one day before assay is to
be run.)
In 125ml PBSG buffer, add: In 65 ml PBSG buffer, add:
0.65g Charcoal
1.25g Charcoal
75mg (0.075 g) Dextran
150mg (0. 15 g)Dextran
In 250ml PBSG buffer, add: In 500ml PBSG buffer, add:
5.Og Charcoal
2.5g Charcoal
600mg Dextran
300mg Dextran
B. Assay Protocol

1).
2).

Thaw all frozen reagents and samples completely
Number a set of 12 x 75mm tubes as follows:
Tracer
(*Ag)

Antiserum
(Ab)

DCC

0

100µ1

0

0

200µ1

0

100µ1

0

750µ1

100µ1

0

100µ1

100µ1

750µ1

4-10 Stds.

0

100µ1

1 00µ1

1 00µ1

750µ1

11- Samples

0

100µ1

100µ1

100µ1

750µ1

Tube No.

Buffer

1 Total Counts

950µ1

2 NSB (blank)
3 Bo

Std.or sample
(Ag)

** Total count----no binding

NSB---non specific binding 1-2% of TC
Bo----Total binding 40-50% of TC
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NOTE:

3).
4).
5).
6).
7).
8).
9).
10).
11).
12).
13).
14).
15).

To determine how much volume of sample to use--> make a set of
dilutions, i.e. 1: 5, 1:25, 1: 50, 1: 100. Run these diluted samples and
choose those the data points fall on the linear portion of the standard
curve.

Add 950µ1 PBSG buffer to tube 1
Add 200µ1 PBSG buffer to tube 2
Add 100µ1 PBSG buffer to tube 3
Add 100µ1 of standards to tube 4-10, starting with the lowest concentration level of
standard solution
Add 100µ1 of sample starting in tube 11
Add 100µ1 of tracer to each tube
Startin& with tube 3, add 100µ1 of antiserum to each tube
Vortex and incubate for 1 hr. at room temp and overnight at 4 °C
At least 15 min. before the end of the overnight incubation period, place the DCC in
an ice bath and stir continuously at moderate speed
Except for tube 1, all tubes add 750µ1 DCC each and vortex for 3-5 seconds
Centrifuge 20 min. at 1000 x g and at 4 °C ( except tube 1)
Without disturbing the sediment, decant all of the supernatant from each tube and
place in scintillation vials ( avoid charcoal). Add 10ml scintillation fluid and count on
the scintillation counter
Calculate the percent B/Bo
(cpm of std or sample - cpm ofNSB)
������������������- * 100
(cpm of Bo-cpm ofNSB)

16).

Plot standard curve: B/Bo against Log cone.
* NSB should be 1-2% of the Total count.
* Bo should be 40-50% of the Total count.

C. RIA principle
1.

Preparation of Standard curve:
- fixed amount of Ab (antiserum) and * Ag (3H-eicosanoid)
- known but increasing amounts of cold Ag (standard eicosanoid)

2.

Principle:
I. Ab + * Ag ----> Ab-* Ag + increasing Ag ----> Ab-Ag + Ab-* Ag + Ag + * Ag
II. To remove extra Ag and * Ag by adding activated charcoal with dextran coated.
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The charcoal is coated with cross-linked polysacchoride dextran. The
activated charcoal has very small pore sizes and can bind small molecules
instantaneously, but since they are dextran coated, only the smaller (non
complexed molecules) can penetrate to bind. Therefore Ab-Ag complex will
not be bound to the activated charcoal.
III.Total counts- add no charcoal, Ag or Ab.
Non-specific binding (NSB) - to ensure all the free * Ag binds to the activated
charcoal.
*should be 1-2% of the total counts.
Total binding (Bo) - to make sure the binding sites of Ab are saturated by * Ag.
should be 40-50% of total concentration.
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APPENDIX ID
LOWRY PROTEIN ASSAY
Modified Lowry Protocol
I.

Reagents:
1).

2).
3).

Buffer A:
2. 0% NctiC03
0.4% NaOH
0.16% Sodium Tartrate
1.0% sos

20 g/I
4 g/1
1.6 g/1
10 g/1

10 g/500 ml
2 g/500 ml
0.8 g/500 ml
5 g/500 ml

Buffer B:
4.0% CuS04 *5H20

40 g/1

20 g/500 ml

Buffer C:
Mix 99 parts buffer A with 1 part buffer B to make alkaline copper reagent.
Total
(ml)
50
100
150
200

II.

B
A
Assays
ml
ml
( ) ( )
49.5
0.5
14
1
99
30
148.5 1. 5
48
198
2
64

4).

Buffer D:
Dilute Folin-Ciocalteu 2 N phenol reagent, 1: 1 (v/v) with deionized H20.

5).

Buffer E (prepare fresh):
0. 01% (=O. l mg/ml) BSA in deionized H20

Sample Preparation:
Tissues are homogenized in saline and frozen at -20 °C
After thawing, sample is sonicated to disperse contents and then diluted 1: 5 ( may be
varied from tissue to tissue)
Dilute sample one more time ( 1: 1) with deionized H20
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III.

Standard Curve Preparation (duplicate):
Buffer E
0.0 1% BSA (0. 1 µgLµil
Std I
Std 2
Std 3
Std 4
Std 5
Std 6
Std 7

0 µI
100 µI
200 µI

400 µI
600 µI

( 0 µg) +
(10 µg) +
(20 µg) +
(40 µg) +

(60 µg) +
(80 µg) +

800 µI
1000 µI ( 1 00 µg) +

0.9% saline
1000 µI
900 µI
800 µI
600 µI
400 µl
200 µl
0 µI

IV. Assay procedure:
1).
2).
3).
4).

V.

To 50 µ1 of sample add 1ml of saline (0.9%), duplicate
Add 3ml of reagent C to each sample and standards. Incubate at room
temperature for 15 min.
Add 300 µI of diluted ( 1: 1) Folin-Ciocalteau (reagent D) to each sample and
standards; vortex vigorously
Incubate for 45 min. at room temperature and read at 660nm against the
blank.

Reference:
Lowry, O.H. Rosebrough, N.J., Farr, A.C. and Rondall Ross J.J. Biol. Chem. 193
(1951): 265.
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APPENDIX IV
RELATIONSHIP OF P-CATENIN AND Bcl-2 EXPRESSION TO SULINDAC
INDUCED REGRESSION OF INTESTINAL TUMORS IN MINI+ MICE
Michael F. McEntee, Chun-Hung Chiu, Jay Whelan
This manuscript has been submitted in similar format to Cancer Research

ABSTRACT
Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause regression of intestinal
tumors in humans and laboratory rodents, but relatively little is known about the mechanisms
involved. Although cyclooxygenase-2 appears to have a role in tumor growth, it is not yet
clear whether blocking prostaglandin synthesis entirely accounts for the anti-tumor activity
ofNSAIDs. Previous work has examined the affects of various manipulations on tumor load
in order to deduce mechanistic conclusions without examining the regressing tumors
themselves. W e recently showed that the NS AID sulindac rapidly decreases the small
intestinal tumor load in Min mice but does not appear to have the same impact on colonic
lesions. In the present study, we have directly examined tumors harvested from Min mice
during sulindac-induced regression, and after prolonged treatment (20 days) at which point
the tumor load has stabilized. Using immunohistochemistry with morphometrics (for

P

catenin) and a scoring scheme (for Bcl-2), we found a �50% decrease in P-catenin (p= 0. 001)
and diminishing Bcl-2 (p=0. 019) in small intestinal tumors undergoing sulindac-induced
regression when compared to those from untreated animals. In contrast, P-catenin and Bcl-2
147

staining in small intestinal tumors from animals treated for 20 days was not significantly
different from untreated controls. There was also no significant difference in staining for
either protein in any of the colonic tumors, regardless of treatment status . These findings
suggest that modulation of P-catenin may occur during NSAID-induced regression of
intestinal adenomas, and that Bcl-2 may confer resistance to these effects.

INTRODUCTION
Development of colorectal cancer, from the appearance of benign adenomatous
polyps to metastatic carcinoma, involves a series of genetic mutations ("hits"), the earliest
often involvingtheAPC gene (1, 2). Individuals affected with familial adenomatous polyposis
(FAP) carry a germline mutation in APC and mutational damage or loss of the second wild
type allele initiates intestinal tumor formation (3, 4). Somatic mutations resulting in loss of
full length APC protein also occur early in spontaneous forms of the disease ( I). The protein
is nonnally up-regulated as cells exit small intestinal crypts or near the luminal surface of the
colon and is believed to have a role in controlling cell migration, apoptosis, and possibly
proliferation (5). An important molecular function ofAPC is regulation ofcytoplasmic pools
of P-catenin. P-Catenin is a necessary component of the E-cadherin adhesion complex and
a transduction molecule for the Wnt-1 (Wingless - in Drosophila) signaling cascade,
cooperating with at least one other factor (Lef-1/TCF) in transcriptional regulation of as yet
incompletely described genes ( 6-9). APC contributes to a degradation process that eliminates
cytoplasmic P-catenin molecules not bound to E-cadherin and thereby down-regulates P
catenin signaling (5). Although the biologic role of this signaling cascade in mammals is not
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fully understood, loss of APC function results in increased levels of free P-catenin in the
cytoplasm and nucleus where it presumably effects some aspect of cell behavior ( I O).
Clinical studies indicate that non-steroidal anti-inflammatory drugs (NSAIDs) cause
regression ofpre-existing adenomas in FAP patients ( 11) but the mechanism(s) is still a matter
of speculation. One probable affect of NSAIDs on these tumors is induction of apoptosis
(12-17). Bcl-2 is a key regulatory antagonist of apoptosis and it has been shown that over
expression of this protein commonly occurs relatively early in the progression of colorectal
carcinogenesis (18-20).
The Min mouse model has been used by a number of laboratories to investigate the
affects ofNSAIDs on intestinal tumor biology ( 14, 2 1, 22). As in humans with FAP, Min
mice carry a germline mutation in APC and develop multiple intestinal adenomas following
spontaneous loss of the wild type allele (2 3). In a recent report, we showed that the NSAID
sulindac causes very rapid regression of pre-existing tumors in Min mice and is necessary for
sustained control of tumor numbers in the intestinal tract (24). In the present study we have
looked at the distribution of P-catenin, APC and Bcl-2 in Min mouse tumors before and after
sulindac treatment in an effort to correlate molecular changes with tumor behavior and
responsiveness to NSAIDs.

METHODS

Tissue samples were obtained during the course of a previously reported study and
details of the experimental protocol are presented therein (24).In brief, heterozygous Min/+
mice (Min) were obtained from Jackson Laboratories (Bar Harbor, l\ffi) at approximately 3 5
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days of age and immediately started on a powder diet (AIN-93G; Dyets, Inc., Bethlehem,
PA).Sulindac (Sigma Chemical Co., St.Louis, MO) was added to the diet at 320 ppm for
the treatment groups. Mice were randomly assigned to 4 different groups:
Controls (no sulindac supplementation) sacrificed at 80 days of age.
Sulindac starting at 78 days of age, sacrificed at 80 days (2 days on sulindac).
Sulindac starting at 78 days of age, sacrificed at 82 days ( 4 days on sulindac).
Sulindac starting at 78 days of age, sacrificed at 98 days (20 days on sulindac).
All animal procedures were approved by the University of Tennessee Animal Care and Use
Committee and were in accord with the NIH Guide for the Care and Use of Laboratory
Animals (NRC 1985). At sacrifice, the entire intestinal tract was removed, flushed with cold
(4°C) phosphate buffered saline (PBS) and opened longitudinally. Tissue samples were
harvested under a dissecting microscope and fixed in 10% neutral buffered formalin. Four
µm paraffin embedded sections were placed on Probe-ON Plus slides (Fisher Scientific,
Pittsburgh, PA ) and immunohistochemically stained using the standard indirect peroxidase
biotin-streptavidin technique. Sections to be stained for Bcl-2 were pretreated with a
microwave antigen retrieval procedure using 10 mM citrate buffer at pH 6 (IO minutes). All
sections were pre-blocked with 3% H202 in PBS ( 15 minutes) and normal goat serum
blocking reagent (50 minutes; BioGenex, San Ramon, CA). Sections were incubated for 1
hour at room temperature with antibodies to P-catenin (cat. #C l9220, 0.5 µg/ml;
Transduction Laboratories, Lexington, KY), or the carboxyl-terminus ofAPC ( cat. #sc-896;
2.5 µg/ml; Santa Cruz Biotechnology, Santa Cruz, CA), or overnight at 4°C with rabbit anti
mouse Bcl-2 (cat. #15616E, 1: 300; PharMingen, San Diego, CA). Sections were then
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incubated with biotinylated anti-mouse or anti-rabbit immunoglobulin (50 minutes, room
temperature) followed by streptavidin-peroxidase link ( 40 minutes, room temperature;
BioGenex). Localized peroxidase conjugates were visualized with 3, 3'-diaminobenzidine
(DAB; BioGenex) and sections were lightly counter stained with hematoxylin. Internal
positive controls included normal mucosal epithelial cells or lymphocytes (for Bcl-2). Primary
antibody was eliminated or an irrelevant antibody substituted in its place as negative controls
for each set. For APC, additional controls included preincubation (overnight at 4°C) of 1 µg
antibody with 11 µg APC peptide (cat #sc-896P; Santa Cruz Biotechnology) which
eliminated positive staining.
Staining was analyzed subjectively and, for P-catenin, objectively by morphometry.
All evaluations were done on coded slides without knowledge of the source of the tumor.
Subjective evaluation entailed direct comparison of staining in the tumors to components of
the adjacent normal intestinal mucosa. For Bcl-2, a scoring scheme was based on comparison
to normal crypt epithelial cells in immediately adjacent areas of small intestinal or colonic
mucosa: no staining = O; a staining gradient from positive deep in the tumor (at level of
adjacent crypts) to negative in upper regions = 1 (i.e. "normal" distribution pattern); staining
in both the deeper and upper regions of the tumor (above the level of the adjacent crypts) that
was equal to or greater than that of the crypts focally/multifocally = 2, and diffusely = 3. For
APC, tumor staining was compared to epithelial cells of the adjacent small intestinal villi and
surface of the colon which are normally positive for this antigen (25, 26).
All morphometric measurements on P-catenin stained sections were done at a fixed
magnification ( 4X objective) and illumination using BioQuant/TCW Image Analysis software,
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version 2. 2 (R&M Biometrics, Nashville, TN). Tumors were manually outlined on the screen
to give an area expressed in pixels. Abnormal P-catenin staining was measured by empirically
adjusting the color ''threshold" setting for a typical untreated small intestinal mass to
demarcate only regions with increased cytoplasmic/nuclear staining; all other tumors were
then evaluated at the same setting. Demarcated areas within each tumor were summed to
give a total area stained (in pixels) within the outlined tumor mass. P-Catenin data represent
the percentage of each tumor to over-express P-catenin in abnormal intracellular locations as
determined by a uniformly applied protocol of tissue handling, staining, and analysis.
All data were tested for normality. P-Catenin data was log transformed and analyzed
by analysis of variance (ANOVA) using Th1P software (SAS Institute Inc., Cary, North
Carolina). Dunnett's pairwise comparison test was used to determine differences (p<0. 05)
between the experimental groups and untreated controls. The Bcl-2 data consisted of discrete
numeric values and could not be normalized. Bcl-2 data was therefore analyzed using a
Kruskal-Wallis non-parametric test for individual pairwise comparisons, followed by a
Bonferroni's adjustment for significance. Spearman's correlation and Kendall's tau-b tests
were applied to the Bcl-2 data for analysis of trend and significance was established at
p<0.05.

RESULTS
P-Catenin

Normal mucosa! epithelial cells of the small intestine and colon were variably, often
weakly, positive under the described staining protocol; more uniform and darker staining
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could be achieved by increasing the concentration of anti-P-catenin antibody or the length of
its incubation with the tissues. Staining was always restricted to the lateral cell membranes
and there was no consistent difference in reactivity between the colon and small intestine, or
between the crypt and surface epithelium. The staining intensity of neoplastic cells in the
small intestine and colon was distinctly increased, in comparison to adjacent normal
epithelium, and concentrated in the cytoplasm and/or nucleus (Figure I , insert) with little
evidence of membrane staining. In most small intestinal tumors, the greatest staining was
restricted to the deeper and lateral aspects of the mass (Figure I). In the smallest lesions,
consisting of single cystic expansions of the crypt (Figure 2) or lesions that had not yet
progressed much beyond the involvement of one or two villi, staining was typically more
widespread with a substantially greater percentage of positive cells than the majority of small
intestinal tumors evaluated (mean = 6 1 . 8% versus 23 . 1%; p< 0.0001). In comparison to
lesions ofthe small intestine, colonic tumors had significantly greater P-catenin staining (Table
I ; p=O. 0009) with a more uniform distribution from the base of the mass to the surface
(Figure 3). The relative intensity and intracellular pattern of staining in neoplastic colonic
epithelial cells was similar to that of cells fonning small intestinal lesions.
As shown in Table I , P-catenin staining decreased significantly in small intestinal
tumors within 2 days of sulindac treatment (p<0.0009). Although fewer tumors were
available for evaluation, this decrease was also evident after 4 days of sulindac treatment
(p=0.00 1). In contrast, P-catenin in tumors from animals maintained on sulindac for 20 days
was not significantly different from untreated controls (p=O. 782). The pattern of staining in
tumors from all treated animals resembled untreated controls in that reactivity was
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Figure A.I.

Tumor from the small intestine of an untreated Min mouse, stained
for P-catenin. Staining was generally most intense in deeper
aspects of small intestinal tumors where the cytoplasm and nucleus
of neoplastic cells were strongly reactive (insert). P-Catenin
staining in adjacent normal epithelial cells was restricted to the
intercellular membranes (lower left of insert).
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Figure A 2.

Early cystic lesion from the small intestine of an untreated Min
mouse with over-expression of cytoplasmic and nuclear P-catenin.
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Figure A. 3.

Colonic tumor from untreated Min mouse stained for P-catenin.
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predominantly in the deep to lateral aspects of the lesions. These cells stained in their
cytoplasm and nuclei, as for untreated tumors, without an apparent increase in cytoplasmic
membrane reactivity. The mean area of small intestinal tumors analyzed from all treatment
groups was less than that of untreated controls and this difference was significant (p<0. 05)
for the 2 day treatment group (data not shown).
P-catenin staining in colonic tumors treated with sulindac for 2, 4 or 20 days tended
to be slightly less than in untreated tumors (Table I ) but differences were not statistically
significant (all p values � 0. 30).There was no morphologic distinction in P-catenin staining
intensity or distribution. There was also no significant difference in the size of the colonic
tumors evaluated from the different treatment groups (data not shown).
APC
APC staining in normal small intestinal epithelial cells was greater over villi than in the
crypts, where cells varied from negative to weakly positive. Reactivity in villus epithelial cells
was predominantly cytoplasmic but occasionally the lateral cell membranes were delineated.
A similar pattern of staining was found in the colon where deep crypt cells were negative and
luminal epithelial cells were positive. Tumor cells in the small intestine and colon from
untreated control animals were negative to weakly positive (comparable to that of normal
crypt epithelium) and always less than that of the adjacent mature epithelium lining normal
villi or the luminal colonic mucosa (not shown). There was no increase in APC staining in
any of the small intestinal or colonic tumors from animals treated with sulindac for 2, 4 or 20
days.
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Table A. I.

Mean percent P-catenin staining and Bcl-2 scores for small intestinal (SI) and
colonic tumors from untreated Min mice and those on sulindac for 2, 4 and 20
days.

Treatmenta

Mean %
P-catenin
SI Tumors
(number)

Mean %
P-catenin
Colonic Tumors
(number)

Mean Bcl-2
Score
SI Tumors
(number)

Untreated
controls
2 days Sulindac

2 3. l b ±2.6
(n=50)

60. 0b ±9. 7
(n= 7)
54. 0b ±9. 3
(n= 3)
42. 3b ±2. 4
(n= 3)
40.0b ±11.0
(n= 2)

2. 34b ±0. 14
(n= 38)
1.95b ±0.18
(n= 40)
1. 38b ±0.50
(n=8)
2. 45b ±0.18
(n= 20)

12. l c ±2. 8

(n= 39)

4 days Sulindac
20 days Sulindac

6.8 c ±3 . 6

(n=6)
26. 7b ±6. 5
(n=l 8)

Mean
Bcl-2
Score
Colonic
Tumors
(number)
3. 0b ±0. 0
(n=5)
3. 0b ±0.0
(n= 3)
3. 0b ±0. 0
(n= 2)
3. 0b ±0. 0
(n= 3)

Seventy-eight day old Min mice were treated for 2, 4, or 20 days with sulindac as previously
described (24). Untreated controls were sacrificed at 80 days of age. P-catenin data was
generated using morphometrics and indicates the relative extent of staining in individual
tumors. Bcl-2 data was derived from a scoring system, also based on the amount and
distribution of staining in the individual tumors, with higher numbers indicating more
widespread Bcl-2.
b
Values in each column with a different superscript letter are significantly different at p <
0.05. The downward trend in small intestinal Bcl-2 scores from untreated controls to the 2
and 4 day treatment groups is significant at p=O.019.
a
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Bcl-2
Many lymphocytes in the lamina propria were positive for Bcl-2 and intraepithelial
lymphocytes were often strongly reactive. The pattern of staining for Bcl-2 in normal
epithelial cells of both the small intestine and colon was similar, but quantitatively distinct.
In the small intestine, there was a faint homogenous to granular staining of the cytoplasm in
normal crypt epithelial cells that was absent in epithelium above the crypt-villus junction
(Figure 4). This reactivity for Bcl-2 was not as strong as that seen in deep crypt cells of the
colon, where staining also rapidly decreased to negative in cells higher up the crypt and on
the luminal smface. Neither the colonic nor small intestinal crypt epithelium stained as
intensely as normal intraepithelial lymphocytes. Small intestinal tumors showed several
different patterns of staining for Bcl-2. Reactivity varied from diffusely less than that of
normal crypt epithelium (negative), to diffusely positive (comparable to or slightly greater
than that of crypt epithelium) (Figure 5), to an intermediate pattern with staining in deeper
tumor cells but none above the level of adjacent crypts (i.e. distribution similar to the normal
mucosa). The mean Bcl-2 staining score for untreated small intestinal tumors was 2. 34 (Table
1), with a score of 1 indicating essentially the same reactivity as the normal mucosa. Cells in
some of the smallest lesions stained for Bcl-2 above the level of the adjacent crypts (Figure
4). In some serially sectioned small intestinal tumors, cytoplasmic reactivity for Bcl-2 co
localized with cytoplasmic/nuclear P-catenin. Colonic tumors were more strongly positive
for Bcl-2 than their small intestinal counterparts with reactivity throughout most lesions and
little evidence of a staining gradient. Staining of most colonic tumor cells was equal to or
greater than that of the adjacent normal crypt epithelium and in some instances showed
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Figure A.4.

Cystic lesion (same as in Figure 2) from the small intestine of an
untreated Min mouse stained for Bcl-2. Crypt cells and the cystic
lesion are weakly positive for Bcl-2 whereas epithelial cells above
the crypt-villus junction are negative.Intraepithelial lymphocytes
are strongly positive for Bcl-2 (arrow).
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Figure A.5.

Edge of small intestinal tumor from untreated Min mouse stained
for Bcl-2. Most of the tumor cells are positive for Bcl-2 whereas
the mature villus epithelium of the adjacent mucosa is negative.

16 1

increased reactivity around nuclear membranes (Figure 6).
In small intestinal tumors there was a sequential decrease in the mean Bcl-2 score after
2 and 4 days ofsulindac treatment (Table I ). There was no difference between Bcl-2 staining
in control tumors and those from animals on sulindac for 20 days (p>0.5). A lthough
comparison of the 4 day group to untreated controls yielded a low p value (0.0425), this was
not statistically significant after applying Bonferroni 's adjustment which indicated significance
only at p<0.017. However, the trend in Bcl-2 scores to decrease from untreated controls to
the 2 and 4 day treatment groups was statistically significant (p=0 .019). A ll colonic tumors
from treated and untreated animals stained similarly for Bcl-2 and were given a score of 3.

DISCUSSION
The earliest molecular event that typically heralds the appearance ofintestinal tumors
is an APC mutation(s) which results in loss of the full-length protein and an accumulation of
P-catenin in the cytoplasm and nucleus of affected cells ( I , 5, 10). We have confirmed this
in Min mouse tumors and have further shown that cystic crypts in the small intestine,
previously described as the earliest stage of tumor growth (27), are also strongly reactive for
nuclear and cytoplasmic P-catenin. These findings are consonant with an initiating somatic
mutation in APC, resulting in loss of heterozygosity, and the lack of imrnunohistochemical
reactivity for the carboxyl-terminus of APC in these lesions (25, 26).
There was clearly a greater amount of P-catenin in tumor cells than in the adjacent
normal mucosal epithelium. Staining in normal cells, always restricted to the lateral cell
membranes, was often weak or negative under the described staining protocol whereas tumor
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Figure A.6.

Bcl-2 staining in colonic tumor cells distinguishes them from the
adjacent non-neoplastic epithelium. Bcl-2 reactivity in tumor cells
often outlines the nuclear envelope.
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cells were darkly stained across their cytoplasm and/or nucleus. A staining gradient was
evident in small intestinal tumors due to greater P-catenin reactivity in deeper aspects of these
lesions. This is not believed to reflect a qualitative change in the intracellular distribution of
P-catenin because increasing the concentration or incubation period ofanti-P-catenin antibody
in the staining protocol increased cytoplasmic/nuclear staining in the upper regions of these
tumors without an increase in membrane staining (not shown). It is worth emphasizing that
the staining conditions were identical for all samples and, as sue� reflect the relative amount
of P-catenin in various intracellular locations and in various regions of both the tumors and
the normal mucosa. An explanation for this pattern of P-catenin staining in small intestinal
tumors is not obvious. We did not detect a similar gradient in the normal mucosa nor in
colonic tumors. Although a gradient has been previously described in the normal intestinal
mucosa, concentrations increased towards the lumen rather than towards the submucosa (I 0,
28).
Non-steroidal anti-inflammatory drugs have been shown to impact on intestinal
tumor growth and although COX-2 is apparently important in this process ( 14, 29, 30),
evidence indicates that other mechanisms are involved which may mediate the affect( s) of
NSAIDs ( 1 5, 1 7, 31, 32). We have shown in this study that there is a significant decrease in
P-catenin in small intestinal tumors from animals actively experiencingNSAID-induced tumor
regression.In a previous study these lesions were shown to undergo regression after only 2
to 4 days of sulindac treatment, with little further change in tumor load after 20 days or more
of drug administration (24). P-catenin staining in small intestinal tumors from animals treated
with sulindac for 2 days was approximately half that in untreated tumors, with a further
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reduction after 4 days of treatment . This decrease does not involve a change in the
intracellular distribution of the protein (i .e. , no increase in membrane staining), but may be
due to a decrease in total P-catenin levels such that fewer cells are immunohistochemically
reactive. Since APC staining did not increase in tumors treated with sulindac for 2 or 4 days,
the decrease in P-catenin was not attributed to repopulation with normal cells (i.e., those
containing a wild-type allele). In contrast to the 2 and 4 day treatment groups, the
percentage of P-catenin staining in small intestinal tumors harvested from animals on sulindac
for 20 days was essentially the same as in tumors from untreated animals. Similarly, P-catenin
did not decrease to a significant degree in colonic lesions from any of the treated animals.
Decreased P-catenin in tumors undergoing NSAID-induced regression suggests a cause-effect
relationship, but it remains to be proven whether or not this represents a primary effect of the
drug.
It is possible that by decreasing P-catenin, the tumorigenic defect initiated with
loss of full length APC protein could be at least partially corrected and thereby reestablish
more normal cellular behavior . Cell migration is impaired by stabilization of the E-cadherin
adhesion complex and up-regulation of E-cadherin expression, both of which may occur with
increases in cytoplasmic P-catenin secondary to loss of APC (8, 33, 34) . It was recently
reported that non-neoplastic intestinal epithelium of the Min mouse contains more P-catenin
than wild-type mice and that sulindac reduces these levels while increasing the relatively slow
rate of cell migration out of the crypt and onto the villus (35). If sulindac modulates

P

catenin levels in tumor cells that lack full length APC, as it does in normal Min intestinal
epithelium, P-catenin degradation would have to involve processes other than those mediated
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by APC andGSK3P (5). It remains to be determined whether this putative NSAID effect is
transcriptional in nature, or involves some other constituent ofthe normal post-transcriptional
degradation pathway that might compensate for the lack of APC. Conductin was recently
identified as a novel component of the cytoplasmic APC-GSK3 P complex and an important
contributor in P-catenin degradation (36). Behrens, et al. also showed that over-expression
of conductin in SW480 cells decreased levels of cytoplasmic and nuclear P-catenin even
though these cells lack full-length APC protein (36). Could NSAIDs up-regulate conductin
expression in Min mouse tumors and thereby decreasing P-catenin levels? Alternatively,
another recent report showed that proteolysis of P-catenin may occur during apoptosis,
apparently due to the activity ofa caspase( s) and presumably without the intervention of APC
(37).
NSAIDs are currently believed to induce apoptosis in intestinal tumors (12-17).
One of the more important apoptosis regulatory molecules is Bcl-2, which inhibits this form
of cell death under most conditions (38). Increased levels of COX-2 can result in higher
levels ofBcl-2 and resistance ofintestinal epithelial cells to apoptosis (39). Since COX-2 may
be elevated in tumors ofMin mice and FAP patients (14, 30), Bcl-2 could also be contributing
to the biology of these lesions.
We found weak staining for Bcl-2 in the normal crypt epithelial cells of the small
intestine and stronger reactivity in normal colonic crypt epithelium. Although others have
also described Bcl-2 expression in both small and large intestinal crypts (18, 40), some
suggest that Bcl-2 is only found in the colonic crypt epithelium ( 41, 42). While this
discrepancy might be explained by variation between individual laboratories in application of
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immunohistochemistry, our findings do indicate higher Bcl-2 levels in crypt epithelium of the
colon than the small intestine. It is unclear how this distinction might be related to the relative
number of lesions that spontaneously develop in the large and small intestines of these mice.
In aggregate, Bcl-2 staining in small intestinal tumors from untreated Min mice
was interpreted to indicate over-expression of this protein because of frequent staining ( �
crypt epithelium) in upper regions of the masses, whereas adjacent villus (mature, non
neoplastic) epithelial cells were negative. Colonic tumor cells also stained for Bcl-2 with an
intensity comparable to the normal colonic crypt epithelium. As with relative staining
intensities in the large and small intestinal mucosa, colonic tumors were more strongly
positive than those in the small intestine. One potential implication of this may be reflected
in the apparent insensitivity ofMin mouse colonic tumors to NSAID-induced regression (22,
24), providing it occurs through apoptosis. There was no indication that Bcl-2 staining
changed in colonic tumors after treatment with sulindac. It is not yet clear whether this
sustained elevation ofBcl-2 represents a barrier to drug-induced apoptosis, or whether the
upstream mechanisms responsible for initiation ofapoptosis and down-regulation ofBcl-2 are
lacking in these cells.
In contrast to colonic lesions, which contain higher levels ofBcl-2, small intestinal
adenomas showed a significant sequential decrease in Bcl-2 staining after 2 and 4 days of
sulindac treatment. There was no difference in Bcl-2 scores between untreated tumors and
those that had been exposed to sulindac for 20 days. We hypothesize that this later group
represents a subset of resistant small intestinal lesions that escape the affects of sulindac (24).
When taken together, the colonic and small intestinal data suggest that inherent (or pre1 67

treatment) levels ofBcl-2 may explain the difference in sensitivity of these two anatomically
distinct sets of lesions to sulindac-induced regression. Whether the sustained elevation of
Bcl-2 in small intestinal tumors after 20 days of treatment is responsible for their resistance
to sulindac remains to be determined. A reduction in Bcl-2 during sulindac-induced
regression would, however, be permissive for increased rates of apoptosis ( 39). In support
of a potential relationship between Bcl-2 and sulindac-induced down-regulation of P-catenin,
Brancolini, et al. showed that Bcl-2 blocked the proteolysis of P-catenin that accompanied
apoptosis ( 3 7).
The molecular mechanisms responsible forNSAID-induced regression ofintestinal
tumors are only starting to be elucidated. APC mutation is a key element in the early steps of
intestinal tumorigenesis and regulation of P-catenin is an important function of the normal
APC protein (5). Our results suggest that the NSAID sulindac may at least partially correct
the imbalance in intracellular P-catenin that results from mutational loss of full-length APC
protein. If proved true, this suggests a potentially important endpoint in further defining the
mechanism of action for sulindac, and perhaps other NSAIDs, in controlling intestinal
tumorigenesis. Neither �-catenin nor Bcl-2 levels seem to change in sulindac resistant
tumors, but the interaction of these proteins during sulindac-induced regression and any
possible link to the arachidonic acid cascade through COX-2 remains to be defined. While
it has been suggested that inhibition of prostaglandin synthesis does not fully explain the anti
tumor effects ofNSAIDs ( 15, 17, 24, 32), COX-2 activity clearly has a role in tumor growth
and NSAID-induced regression ( 14, 29). It was recently shown that PG:Ez can increase Bcl-2
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and inhibit apoptosis in human colonic cell lines ( 43), but this is discordant with other studies
which demonstrate NSAID-induced tumor regression and apoptosis to be independent of
eicosanoid levels ( 15, 17, 24, 32).
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APPENDIX V
STRUCTURES AND DOSES OF NSAIDs
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Figure A. 7.

Chemical structures of sulindac and its metabolites.
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Figure A 8.

Chemical structures of aspirin and indomethacin.
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Table A.2.

Doses of sulindac, aspirin and indomethacin

Sulindac

Aspirin

Indomethacin

C2Jf17F03S

C Jf8 0 4

C 1Jf16CIN0 4

F.W.

3 56.4

1 80.2

3 57. 8

ppm

320

400

9

mg/mouse/day

0. 83

1 .06

0.023

mg/Kg B.W./day

30.5

43 . 8

0. 89
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